 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 1 of 81  
 
CRD_971  
ARIES HM3  
Antiplatelet  Removal and Hemocompat Ibility EventS with the HeartMate 3 Pump  
 
Version  C 
Date  MAR 13 , 2020 
Steering Committee  Mandeep Mehra  MD, MSc, FRCP (Lon) - Chair   
Nir Uriel MD, MSc   
Francis Pagani MD, PhD   
Ulrich Jorde MD 
Jason Katz MD, MHS  
Finn Gustafsson MD, PhD  
Ivan Netuka MD, PhD  
Planned Number of Sites  Up to 50 sites  
Geographies  International  
Clinical Investigation  Type  Prospective, randomized, double -blinded, placebo -controlled 
clinical investigation of advanced heart failure patients treated 
with the HM3 with two different antithrombotic regimens: vitamin 
K antagonist with aspi[INVESTIGATOR_403963] K antagonist with 
placeb o 
Sponsor  Abbott  
168 Middlesex Turnpi[INVESTIGATOR_403964], MA [ZIP_CODE]  
[LOCATION_003] 
Randomization and Treatment 
Arm Medication  Logistics  WebEZ (ALMAC Clinical Services)  
Electronic Data Capture Software  Oracle Clinical  
CIP Author (Current Version)  Daniel Crandall, PhD  
Abbott Medical Expert  [INVESTIGATOR_404086], MD, FACS, FRCS (C), FAHA  
  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ADDRESS_509308] read and agree to adhere to the clinical investigation plan and all regulatory requirements 
applicable in conducting this clinical investigation.  
 
 
Site Principal Investigator  
 
[INVESTIGATOR_115653]:  
Signature:  
[CONTACT_1782]:  
 
  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ZIP_CODE] Rev. F  Page 3 of 81  
 
 
TABLE OF CONTENTS 
 
 1.0 INTRODUCTION ..............................................................................................................................  9
1.1 Background and Rationale ...........................................................................................................  9
Background ...........................................................................................................................  9
Rationale for Conducting this Clinical Investigation .............................................................  10
2.0 CLINICAL INVESTIGATION OVERVIEW ......................................................................................  11
2.1 Clinical Investigation Objective ................................................................................................... 11
2.2 Hypothesis .................................................................................................................................. 11
2.3 Device(s) To Be Used in the Clinical Investigation .....................................................................  11
Indication for Use ................................................................................................................  12
Description of the Device(s) Under Investigation ................................................................  13
Device Accountability ..........................................................................................................  13
2.4 Treatment Arm Medication .........................................................................................................  13
Project Management ...........................................................................................................  13
Treatment Arm Blinding .......................................................................................................  14
Treatment Arm Bottle Dispensing ........................................................................................  14
Antithrombotic Therapy .......................................................................................................  14
Treatment Arm Medication Accountability ...........................................................................  15
Aspi[INVESTIGATOR_403965] .................................................................................................... 15
3.0 CLINICAL INVESTIGATION DESIGN ............................................................................................  15
3.1 Clinical Investigation Procedures and Follow-up Schedule ........................................................  16
3.2 Measures Taken to Avoid and Minimize Bias .............................................................................  18
3.3 Suspension or Early Termination of the Clinical Investigation ....................................................  18
4.0 ENDPOINTS .................................................................................................................................. 19
4.1 Primary Endpoint and Rationale ................................................................................................ . 19
4.2 Secondary Endpoint ...................................................................................................................  19
4.3 Descriptive Endpoints .................................................................................................................  20
5.0 SUBJECT SELECTION AND WITHDRAWAL ...............................................................................  20
5.1 Subject Population ......................................................................................................................  20
5.2 Subject Screening and Informed Consent ..................................................................................  20
Subject Screening ...............................................................................................................  20
Informed Consent ................................................................................................................  20
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ZIP_CODE] Rev. F  Page 4 of 81  
 
5.3 Eligibility Criteria .........................................................................................................................  21
Inclusion Criteria ..................................................................................................................22
Exclusion Criteria .................................................................................................................  22
5.4 Subject Enrollment .....................................................................................................................  22
Enrollment of Medicare Beneficiaries ..................................................................................  22
Historically Under-Represented Demographic Subgroups ..................................................  23
5.5 Subject Withdrawal .....................................................................................................................  24
Incidental Use of Aspi[INVESTIGATOR_403966] .................................................................... 25
5.6 Transition to Open Label ............................................................................................................  25
5.7 Number of Subjects ....................................................................................................................  26
5.8 Total Expected Duration of the Clinical Investigation ................................................................ . 26
6.0 TREATMENT AND EVALUATION OF ENDPOINTS .....................................................................  26
6.1 Avoidance of Additional Antiplatelet Medications .......................................................................  26
6.2 Avoidance of Platelet Function Testing ......................................................................................  26
6.3 Study Activities and Procedures ................................................................................................ . 26
6.4 Baseline ......................................................................................................................................  28
6.5 Implant Procedure ......................................................................................................................  29
6.6 Randomization ............................................................................................................................  30
6.7 Initial Discharge Data ..................................................................................................................  30
6.8 Scheduled Follow-up for All Subjects .........................................................................................  30
Continued follow up beyond 12-months post implant ..........................................................  32
6.9 Unscheduled Visits .....................................................................................................................32
Adverse Events ...................................................................................................................  32
[IP_ADDRESS] Neurologic Adverse Events ..........................................................................................  32
Operative Procedures ..........................................................................................................  32
Hospi[INVESTIGATOR_602] ...................................................................................................................  32
Outcomes ............................................................................................................................  33
6.10 Blinding .......................................................................................................................................  33
6.11 Patient Reported Outcome (PRO) Measure ...............................................................................  33
7.0 ADVERSE EVENTS .......................................................................................................................  34
7.1 Definition .....................................................................................................................................  34
Adverse Event .....................................................................................................................  34
Serious Adverse Event ........................................................................................................  34
Device Deficiency ................................................................................................................  34
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ZIP_CODE] Rev. F  Page 5 of 81  
 
7.2 Device Relationship ....................................................................................................................  34
Unanticipated Serious Adverse Device Effect ([LOCATION_003]DE) .....................................................35
7.3 Adverse Event and Device Deficiency/Device Malfunction Reporting ........................................  35
Adverse Event Reporting .....................................................................................................  35
Unanticipated Serious Adverse Device Effect Reporting to Sponsor and IRB/EC ..............  36
Device Deficiency Reporting ...............................................................................................  36
Adverse Event Reporting to Country Regulatory Authorities by [CONTACT_1034] .....................  36
8.0 STATISTICAL CONSIDERATIONS ...............................................................................................  37
8.1 Analysis Populations ..................................................................................................................  37
Modified Intention to Treat Population (mITT) .....................................................................  37
Intent-To-Treat (ITT) Population  ..........................................................................................  37
8.2 Statistical Analyses .....................................................................................................................  37
Primary Endpoint Hypothesis ..............................................................................................  37
Primary Endpoint Analyses Methodology ............................................................................  38
Secondary Endpoint Analyses .............................................................................................  38
Descriptive Endpoints ..........................................................................................................  38
8.3 Sample Size Calculation and Assumptions ................................................................................  38
8.4 Timing of Analysis .......................................................................................................................  39
8.5 Subgroup Analysis ......................................................................................................................  39
8.6 Multiplicity ................................................................................................................................... 39
8.7 Pooling Strategy .........................................................................................................................  39
8.8 Procedures for Accounting for Missing Data ..............................................................................39
8.9 Planned Interim Analysis ............................................................................................................  39
8.10 Statistical Criteria for Termination ...............................................................................................  39
8.11 Success Criteria .........................................................................................................................  40
8.12 Deviations from Statistical Plan .................................................................................................. 40
9.0 DIRECT ACCESS TO SOURCE DATA/DOCUMENTS ................................................................ . 40
10.0 QUALITY CONTROL AND QUALITY ASSURANCE .....................................................................  40
10.1 Selection of Clinical Sites and Investigators ...............................................................................  40
10.2 Clinical Investigation Finances and Agreements ........................................................................  40
10.3 CIP Amendments ........................................................................................................................  40
10.4 Training .......................................................................................................................................  41
Site Training ........................................................................................................................  41
10.5 Monitoring ................................................................................................................................... 41
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ZIP_CODE] Rev. F  Page 6 of 81  
 
10.6 Deviations from the CIP ..............................................................................................................  41
10.7 Quality Assurance Audit .............................................................................................................42
10.8 Committees ................................................................................................................................  43
Steering Committee .............................................................................................................  43
Data Safety Monitoring Board (DSMB) ................................................................................  43
Clinical Events Committee (CEC) ........................................................................................  43
11.0 DATA HANDLING AND RECORD KEEPI[INVESTIGATOR_1645] ................................................................................  44
11.1 Protection of Personally Identifiable Information ........................................................................  44
11.2 Data Management Plan ..............................................................................................................  45
11.3 Source Documentation ...............................................................................................................  45
11.4 Case Report Form Completion ................................................................................................... 45
11.5 Record Retention ........................................................................................................................  46
12.0 ETHICAL CONSIDERATION .........................................................................................................  46
12.1 Institutional Review Board/Medical Ethics Committee Review and Approval .............................  46
13.0 CLINICAL INVESTIGATION CONCLUSION .................................................................................  46
14.0 REPORTS AND PUBLICATIONS .................................................................................................. 47
14.1 Sponsor Reports .........................................................................................................................  47
14.2 Publication Policy .......................................................................................................................  47
14.3 Trial Registration ........................................................................................................................  47
15.0 RISK ANALYSIS ............................................................................................................................  47
15.1 Anticipated Clinical Benefits .......................................................................................................  47
15.2 Foreseeable Adverse Events and Anticipated Adverse Device Effects ......................................47
15.3 Residual Risks Associated with the Clinical Investigation, as Identified in the Risk Analysis 
Report .........................................................................................................................................  48
15.4 Risks Associated with Participation in this Clinical Investigation ................................................  48
15.5 Possible Interactions with Protocol-Required Concomitant Medications .................................... 48
15.6 Steps Taken to Control or Mitigate Risks ...................................................................................  49
15.7 Risk to Benefit Rationale ............................................................................................................  49
APPENDIX I: ABBREVIATIONS AND ACRONYMS .................................................................................  51
APPENDIX II: DEFINITIONS ....................................................................................................................  54
APPENDIX III: STUDY CONTACT [CONTACT_7533] .................................................................................  63
APPENDIX IV: INFORMED CONSENT FORM ........................................................................................  64
APPENDIX V: MONITORING PLAN .........................................................................................................  65
APPENDIX VI: DEVICE POSITION SUBSTUDY PROTOCOL ................................................................  66
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 7 of 81  
 
APPENDIX VII: REVISION HISTORY  ................................ ................................ ................................ ...... 74 
APPENDIX VIII: CIP SUMMARY  ................................ ................................ ................................ ..............  76 
APPENDIX IX: REFERENCES  ................................ ................................ ................................ .................  80 
  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 8 of 81  
 
COMPLIANCE STATEMENT:  
This clinical investigation  will be conducted in accordance with this Clinical Investigation Plan , the 
Declaration of Helsinki, applicable Good Clinical Practices and regulations (e.g., US 21 CFR Part 50, 21 
CFR Part 56, 21 CFR Part 812 , and OUS ISO14155 :2011 ) and the appropriate local legislation(s). The 
most stringent requirements, guidelines or regu lations must always be followed. The conduct of the 
clinical investigation  will be approved by [CONTACT_144709] (IRB)/Ethics 
Committee (EC) of the respective investigational site and by [CONTACT_179190].  
  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ZIP_CODE] Rev. F  Page 9 of 81  
 
1.0 INTRODUCTION 
Heart failure (HF) is a growing epi[INVESTIGATOR_901], with 915,000 new cases diagnosed each year, resulting in over 
1 million hospi[INVESTIGATOR_403967] (US) healthcare system over $[ADDRESS_509309] devices (LVAD) are increasingly being used for treating patients with advanced heart failure as they have demonstrated improved survival over optimal medical management
2. 
Progressively improving outcomes with newer LVAD technology has led to LVAD therapy becoming a 
mainstay in the treatment of advanced heart failure3, however, LVAD therapy has been beleaguered by 
[CONTACT_404024] – namely thrombosis, stroke and bleeding4. Within the 
prospective randomized multicenter MOMENTUM 3 clinical trial, the HeartMate 3 (HM3) Left Ventricular 
Assist System (LVAS; Abbott, Chicago, IL, Study Sponsor) showed a decrease in hemocompatibility 
related adverse events relative to the HeartMate II (HMII) LVAS (Abbott, Chicago, IL)5. This included 
decreases in pump thrombosis6, stroke7-9, and bleeding9 event rates. Despi[INVESTIGATOR_403968] 
a high residual risk of bleeding persists in patients treated with the HM3 LVAD9. Patients implanted with 
the HM3 pump are treated with a combination of antiplatelet and anticoagul ation therapy but the role and 
implications of this regimen in determining the burden of hemocompatibility related adverse events have not been adequately investigated
9,10. Whether antiplatelet therapy is essential in concert with 
anticoagulation in treating such patients remains unknown. 
 
This clinical investigation is a prospective, randomized, double-blinded, placebo -controlled study of 
advanced heart failure patients treated with the HM3 with two different antithrombotic regimens: vitamin K antagonist with aspi[INVESTIGATOR_403969] K antagonist with placebo. The objective of this investigation is 
to study the safety and efficacy of an anti-platelet -free antithrombotic r egimen in patients with advanced 
heart failure treated with the HM3 LVAS.  
 
This clinical investigation will be conducted in accordance with this clinical investigation plan (CIP). All 
investigators involved in the conduct of the clinical investigation will be qualified by [CONTACT_8640], training, or experience to perform their tasks and this training will be documented appropriately. 
1.1 Background and Rationale
 Background 
The CE Mark trial (clinicaltrials.gov identifier: [STUDY_ID_REMOVED]) for the HM3 LVAD was a prospective, multicenter, single arm trial that enrolled 50 subjects at 10 sites. Six-month outcomes from this trial demonstrated 92% (confidence interval 83-97%) survival and led to the CE Mark approval of the HM3. Analysis of longer term data demonstrated a 2-year survival of 74 ± 6%
11. No instances of device 
thrombosis were observed in this cohort at 2 years11. Subjects will be followed through 5 years as a 
condition of CE Mark approval.  
 After approval, the ELEVATE (Evaluating the HeartMate [ADDRESS_509310]-Market 
Approval Setting; clinicaltrials.gov identifier: [STUDY_ID_REMOVED]) registry was initiated to collect real-world data 
(i.e. there were no enrollment criteria) on consecutive HM3 patients at 26 total centers in Europe, Israel , 
Singapore, and Kazakhstan. The study enrolled 463 primary implant patients, 19 pump exchange patients, 
and collected only outcome data on an additional 58 patients who were unable to provide consent due to 
a study outcome (n=57 death, n=1 explant). The ELEVATE trial reported, for the primary implant cohort at 
2-years, actuarial survival of 83.4%, and adverse events of stroke in 10%, suspected pump thrombosis in 
1.5%, and bleeding in 34 %
12. 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ZIP_CODE] Rev. F  Page 10 of 81  
 
 
The MOMENTUM 3 study (clinicaltrials.gov identifier: [STUDY_ID_REMOVED]) was a prospective, randomized, 
multicenter, non-blinded, clinical trial that enrolled 1,028 patients at 69 sites in the US. The study 
randomized patients to receive either the HM3 or HMII LVAD. The study design incorporated an initial 
safety phase that evaluated 30 subjects at 5 sites prior to study expansion13. The primary objective of the 
trial was to evaluate the safety and efficacy of using the HM3 LVAD in indicated patients at two timepoints: 
6 months (short-term  n=294) and 2 years (long- term n=366 )13. The primary endpoint was a composite of 
survival free of disabling stroke or survival free of reoperation to replace or remove the device (for reasons 
other than recovery)14. The secondary endpoint, which the study was powered to assess, was freedom 
from pump exchange through 2-years of follow-up in the full cohort of 1028 patients. All study endpoints were successfully met
6,8,9. The MOMENTUM 3 trial reported the full cohort HM3 actuarial survival at 2-
years as 79.0% and stroke rates of 9.9%, suspected pump thrombosis rates of 1.4%, and bleeding rates 
of 43.7%9. An analysis of the burden of hemocompatibility related adverse events showed improved 
survival free of hemocompatibility related adverse events with the HM3 over the HMII at 6 months5 and 2 
years15. Within the full cohort HM3 arm of MOMENTUM 3, at all time points, a cohort of patients were 
noted without aspi[INVESTIGATOR_246362] a part of their anti-thrombotic regimen, specifically at 6-months n=72/446 (16%), 
at 1-year n=78/371 (21%), at 18- months n=73/314 (23%), and at 2 -years n=64/286 (22%)9. The 
MOMENTUM [ADDRESS_509311]-implant as a condition of 
approval. After full enrollment in the MOMENTUM 3 study, a single arm (HM3 only) continued access 
protocol (CAP) was initiated while the MOMENTUM [ADDRESS_509312] implant.   
 
A single center in Europe has investigated the use of the HM3 with low intensity anticoagulation (INR 1.5-
1.9) in select patients, and reported positive outcomes10. These outcomes lead to the full removal of 
anticoagulation therapy in a subset of the low intensity anticoagulation patients, with favorable outcomes16. 
Additionally two reports from Europe have emerged on their initial experience with warfarin monotherapy 
with the HM317,18. Both studies conclude it may be safe to remove aspi[INVESTIGATOR_403970]3 patients and 
called for further evaluation of the effects of discontinuation of aspi[INVESTIGATOR_403971]3 patients. Specifically, in a multicenter, retrospective, observational study performed at the San Raffaele Scientific Institute in Milan and A.O. Brotzu in Cagliari, Italy, patients were stratified based on bleeding risk; patients with a HAS-BLED 
score ≥ [ADDRESS_509313]-operative bleeding event were considered high risk
17. Patients at high 
bleeding risk were discharged on warfarin monotherapy with INR targeted to 2.0 -2.5 whereas the 
remaining patients were discharged with warfarin (INR 2.0-2.5) and aspi[INVESTIGATOR_248] (100mg/day) antithrombotic 
therapy17. In the other study at the University Hospi[INVESTIGATOR_403972], [LOCATION_008], a retrospective 
analysis of a prospective audit of a change in their institutional standard of care was conducted18. The 
center implemented as standard of care the discontinuation of aspi[INVESTIGATOR_403973] >[ADDRESS_509314] not been adequately investigated
9,10. 
Furthermore, a recent study showed that aspi[INVESTIGATOR_248], in older, healthy adults  without an LVAD, was associated 
with increased risk of major bleeding, including upper gastrointestinal bleeding, without a reduction in 
thromboembolic events including ischemic stroke19. Whether antiplatelet therapy is essential in concert 
with anticoagulation in treating LVAD patients remains unknown. 
 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 11 of 81  
 
Hemocompatibility related adverse events, both thrombotic and hemorrhagic, are highly interrelated. 
Frequently changes to a patient’s anti thrombotic therapy that occur in the setting of hemocompatibility 
related adverse events increase the propensity toward opposing events. Specifically, treatment of a 
thrombotic event with additional antithrombotic intensity may result in a hemorrhagic even t or vise -versa. 
While these events may be commonly discussed discretely, decoupling them in the setting of a patient 
population predisposed to both events is not possible, which can lead to difficulty interpreting the results 
of clinical studies or, in th e worst -case scenario, studies with little or no interpretive value. As such, t his 
study focuses on de novo LVAD implants and the first events, prior to such modifications to the treatment 
arm antithrombotic regimen  while encouraging investigators to maint ain the randomized treatment arm 
therapy as long as clinically permissible , in an effort to avoid such confounding factors.  
 
Bleeding events  with the HM3 , while decreased in comparison to a predicate device, remain burdensome9. 
All major prospective clinical trials conducted with the HM3 (MOMENTUM 3, CE Mark) have been in the 
context of a prescribed  antithrombotic regimen of  aspi[INVESTIGATOR_403974] K antagonist . Within clinical  
studies9,10,16, as institutional  changes to their standard of care18, or in response to increased bleeding risk17, 
modifications to the HM3 anticoagulation regimen have been explored . Prior to the introduction of the HM3, 
which has a decreased thrombotic profile relative to the HMII, studies investiga ting the need for aspi[INVESTIGATOR_403975]20-23. The experience  with the HMII , the improved 
outcomes with the  HM3  and the early experience of single centers exploring modification to the 
antithrombotic regimen in HM3 patients  provide evidence for the clinical equipoise in HM3 antithrombotic 
therapy and forms the basis for randomization of patient s to aspi[INVESTIGATOR_248] (100mg) vs placebo arms within this 
trial.   
2.[ADDRESS_509315] safety or efficacy of the HM3 and may reduce non -surgical bleeding . 
2.3 Device (s) To Be Used in the Clinical  Investigation  
This Clinical Trial investigates  the treatment of advanced heart failure with the HM3 and if  the use of 
antiplatelet  therapy  is required as part of the antithrombotic regimen . Refer to the HM3  Instruction for 
Use (IFU) in your country  for additional detail s.  
 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ZIP_CODE] Rev. F  Page 12 of 81  
 
Table 1 – Device Details 
Device name [CONTACT_26159]/Type Serial/Lot 
Controlled Manufacturer Investigational or 
Market Released 
HeartMate 3 
(HM3) Left 
Ventricular 
Assist System 
(LVAS) [ADDRESS_509316] 
Commercial 
Controls Abbott The HM3 will be 
Market Released in 
all geographies 
included in this 
international study 
 
 
 
Figure 1 – HeartMate 3 LVAD (A) and System during Battery-powered Operation (B):  The HM3 LVAS 
consists of an LVAD with an outflow graft and modular driveline cable, a pump controller and a power 
source (i.e. portable Batteries, Power Module, or Mobile Power Unit). 
 
 Indication for Use  
The HM3 is market released in all geographies participating in this study, therefore refer to the local IFU 
for the local indication.  In the US, the HM3 LVAS is indicated for providing mechanical circulatory support 
in patients with advanced refractory left ventricular heart failure (e.g. pending cardiac transplantation or 
myocardial recovery, or for permanent support). In Europe, the HM3 LVAS is intended to provide long 
term hemodynamic support in patients with advanced, refractory left ventricular heart failure. It is 
intended either for temporary support, such as a bridge to cardiac transplantation (BTT), or as permanent 

 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ZIP_CODE] Rev. F  Page 13 of 81  
 
destination therapy (DT) and it is intended for use inside or outside the hospi[INVESTIGATOR_307]. In Canada, The HM3 
LVAS is indicated for providing mechanical circulatory support in patients with advanced refractory left 
ventricular heart failure (e.g., pending cardiac transplantation or myocardial recovery, or for permanent 
support). 
 Description of the Device(s) Under Investigation 
The HM3 LVAS consists of a centrifugal LVAD with an outflow graft and modular driveline cable, a pump 
controller and a power source (i.e. portable Batteries, Power Module, or Mobile Power Unit). The HM3 
LVAD is comprised of an Inflow Cannula, a Pump Cover, a Lower Housing, a Screw Ring to attach the 
Pump Cover to the Lower Housing, a Motor, the Outflow Graft, the Outflow Graft Clip (if required), and a 
Pump Cable.  
 
The HM3 LVAD has a displacement volume of 80 milliliters and weighs 200 grams. All blood contact[CONTACT_404025] (LVAD body and centrifugal rotor) or gelatin-impregnated woven 
polyester (outflow graft). The HM3 LVAD is designed to reduce adverse events associated with LVAD 
thrombosis. Primary design features include full magnetic levitation and large flow gaps, which minimize 
the shear stress imparted onto the blood elements. 
 
The HM3 Controller is an extracorporeal interface device that receives power from the Power Module, 
Mobile Power Unit, or portable Batteries, and appropriately delivers that power to the HM3 LVAD. It is the 
primary user interface and has several important functions including: 
• operating condition display, 
• source of audible and visible alarms, 
• communication link for transferring event/period log and alarm information, and 
• battery backup in the case of full power disconnection. 
 
The HM3 LVAD and Controller are sterilized using 100% ethylene oxide. Please refer to the local IFU for 
additional information regarding the device used in this clinical investigation.  
 Device Accountability  
All devices used in this study will be commercial stock at each investigative site. The HM3 is commercially 
available and approved for the patient population enrolled in this study; therefore, study specific device 
accountability is not required. The standard commercial practices for device tracking, return and reporting 
to the Sponsor ’s Product Performance Group should be followed in accordance with local practices.  
2.[ADDRESS_509317] a matching 
placebo. Distribution logistics, site inventory management, patient randomization and treatment arm 
medication bottle requisition will be coordinated by [CONTACT_404026]’ WebEZ system. Treatment 
arm medication will be stored in Souderton PA and may be stored in international depot sites administered 
by [CONTACT_404027], Northern Ireland and Singapore, prior to dispatch to sites. Medication 
accountability will be performed at their facility in Durham, NC or may be performed at depot sites in 
Craigavon, Northern Ireland or Singapore. Treatment arm medication accountability will include pi[INVESTIGATOR_403976] - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ADDRESS_509318] within the Abbott electronic data capture system (EDC).  
 
ALMAC Clinical Services is a part of ALMAC Group Limited headquartered at ALMAC House, 20 Seago e 
Industrial Estate, Craigavon, BT63 5QD, Northern Ireland (Registration Number: NI [ZIP_CODE]). 
 
ALMAC Clinical Services responsibilities will be, but not limited to, the following: 
• Treatment arm medication manufacture (blinded aspi[INVESTIGATOR_403977]-to-match), including 
packaging and labelling (due to country-specific requirements treatment arm medication bottle 
labeling  may vary) 
• Patient randomization via the ALMAC WebEZ system 
• Supplying treatment arm medication to sites including maintaining adequa te site supply 
• Providing support dispensing to study subjects via the ALMAC WebEZ system  
• Treatment arm medication accountability, including both used and unused drug bottle returns 
 Treatment Arm Blinding 
This study shall use 100mg aspi[INVESTIGATOR_248], blinded against a placebo-to-match. Sites should reach out to the 
sponsor immediately regarding unblinding questions.  
 Treatment Arm Bottle Dispensing 
Initial dispensing of the treatment arm bottle will occur upon  randomization. Subjects will begin taking the 
treatment arm medication within 24 hours of randomization . Subjects will be resupplied 1 bottle at Month 
3, Month 6, and Month 9 follow-up visits and 2 bottles at month 12 and every 6 months thereafter until 
study closure . Dispensing will be controlled at the sites with the use of ALMAC Clinical Services’ WebEZ 
system. At each dispensing time point, the designated site personnel will log on to the WebEZ system, 
enter information required for randomization or resupply, and requisition a bottle to dispense to the subject 
from the on-site stock.  
 
Each bottle will be tracked by [CONTACT_404028]. The WebEZ system will provide sites with the bottle 
number to be dispensed to a given subject. Bottle details should be tracked per patient by [CONTACT_21127]. Site supply 
and resupply shipments will be automatically controlled by [CONTACT_404026].  
 
If a subject reports a lost or empty bottle of treatment arm medication or is unable to attend a resupply 
visit, the designated site personnel will log onto the WebEZ system to requisition a replacement bottle from 
the onsite supply. The replacement bottle may be shipped overnight to the subject, or the subject may 
choose to retrieve the replacement bottle from the site in person.   Subjects should always be sufficiently supplied with treatment arm medication until their next resupply visit. 
Each bottle will contain [ADDRESS_509319]’s next visit, including the acceptable visit windows. Sites should carefully 
schedule follow up visits to ensure subjects are always sufficiently supplied.  
 Antithrombotic Therapy 
Antithrombotic therapy throughout the study should consist of a vitamin K antagonist (e. g. warfarin, 
fluindione, phenprocoumon , etc.) and the treatment arm medication. No additional anti-platelet agents 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ADDRESS_509320] of care (SOC) with a target 
INR of 2.0-3.0. The use of aspi[INVESTIGATOR_34251] a vitamin K antagonist is normal clinical practice at many centers 
and is part of the HM3 IFU.  
 Treatment Arm Medication Accountability 
To ensure treatment arm medication accountability, all bottles including (if applicable) all unused doses 
will be returned to ALMAC Clinical Services by [CONTACT_779]. Subjects will be instructed to return the bottle and 
any unused doses of the treatment arm medication at each resupply visit.   The bottles and unused doses will be shipped (at the Sponsor’s expense) per country- or region-specific Treatment Arm Medication Accountability Return Instructions. 
 
In the event that a site has several bottles or unused portions to return to ALMAC Clinical Services, return shipments may be combined into a batch shipment. Empty research bottles and unused doses should not be stored on site and should be shipped to ALMAC Clinical Services within [ADDRESS_509321] their response to aspi[INVESTIGATOR_403978] B2 testing. Testing will be performed by a core lab (Corgenix, Broomfield, Colorado). 
To retain the study blind, sites will not receive the results of the test. Samples will be collected and 
processed by [CONTACT_404029], 3, 6, and [ADDRESS_509322]-implant. Samples will be stored frozen at the 
sites until they are shipped (within 15 days of collection; overnight shipment Monday-Thursday with 
sufficient dry ice to retain frozen state) to Corgenix at:  
Corgenix Clinical Laboratory 
ATTN: General Supervisor 
[ADDRESS_509323] 
Broomfield CO [ZIP_CODE]  
 
Additional sample processing, storage, and shipment details will be provided in the ARIES HM3 Aspi[INVESTIGATOR_403979].   
NOTE: Additional antiplatelet testing or platelet function testing, beyond the core lab test, should not be 
performed while patients are on the treatment arm medication, as it may result in un-blinding of the subject 
or the investigator. 
3.0 CLINICAL INVESTIGATION DESIGN 
This is a prospective, randomized, double-blinded, placebo-controlled clinical investigation of advanced 
heart failure patients treated with the HM3 with two different antithrombotic regimens: vitamin K 
antagonist with aspi[INVESTIGATOR_403969] K antagonist with placebo. Subjects will be randomized in a 1:1 
ratio.  
 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 16 of 81  
 
The clinical investigation has been designed to involve as little pain, discomfort, fear, and any other 
foreseeable risk as possible for subjects. Refer to t he Risks Analysis  section of th e clinical investigation 
plan for details .  
 
The clinical investigation  will be conducted at up to 50 centers worldwide . Greater than 50% of the 
patients enrolled in this study will be from centers based in the [LOCATION_002]. The primary  and 
secondary endpoints will be evaluated according to the statistical secti on (Section 8  and in the study 
statistical analysis plan; SAP ). Outcomes for this study include death, transplant, withdrawal or pump 
exchange. All subjects, site,  Clinical Events Committee (CEC), and sponsor personnel  will remain 
blinded to th e randomizat ion scheme until the last ongoing study subject  completes follow -up 
(specifically,  experiences an outcome or  has final study visit ) and all data have been collected and 
adjudicated . Exceptions will be justified in the study blinding plan (e.g. DSMB ). After  a patient reaches 
12-months of follow up, they will continue to be followed every [ADDRESS_509324] ongoing patient reaches 12 -months of follow up. Beginning at the 
12-month follow -up visit, p atients should be requisitioned two bottles of the treatment arm medication to 
cover the 6 months until the next follow up visit.   
3.1 Clinical Investigation Procedures and Follow -up Schedule  
The study f low chart (Figure 2) and the follow -up schedule  of this clinical investigation are described 
below . 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 17 of 81  
 
 
 
Figure 2 – Clinical Investigation  Flow Chart  

 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 18 of 81  
 
3.2 Measures Taken to Avoid and Minimize Bias  
This study is designed to minimize bias by [CONTACT_404030], site  personnel,  sponsor personnel , and 
the CEC to the randomly assigned  treatment regimen.  Furthermore, screening logs will be captured 
including detail s on patients who are excluded from the study only because of investigator mandated 
antiplatelet therapy (presence or a bsence) prior to or after consent to understand any effect of selection 
bias on the generalizability of the study.  
3.3 Suspension or Early Termination of the Clinical  Investigation  
While no formal statistical rule for early termination of the clinical investig ation for insufficient 
effectiveness of the device under investigation is defined  by [CONTACT_941] S ponsor  or Steering Committee , the 
Sponsor reserves the right to discontinue the clinical investigation at any stage or reduce the follow -up 
period with suitable written notice to the investigator. Possible reason(s) may include, but are not limited 
to: 
• Unanticipated adverse device effect (e.g., UADE) occurs and it presents an unreasonable risk to 
the participating subjects  
• An oversight committee (e.g., St eering Committee, DSMB ) makes a recommendation to stop or 
terminate the clinical investigation (such as in the event of higher frequency of anticipated 
adverse device effects)  
o The Data Safety Monitoring Board will create independent rules  for study oversig ht 
including prespecified rules  for recommending cessation of the study , which will be 
captured in the DSMB cha rter. In the event these rules are met, the sponsor  will meet with 
the Steering Committee. The Sponsor  will notify sites and , if agreed with the Steering 
Committee,  enrollment in the study will be paused .  
• Further study progress  is cancelled.  
 
Should the clinical investigation be discontinued by [CONTACT_1034], subjects will be followed per routine 
hospi[INVESTIGATOR_26103] -related AEs reported to  the Sponsor as per vigilance/commercial reporting 
requirements. The investigator shall return all clinical investigation materials (including both partially used 
and unused treatment arm medication bottles ) to ALMAC or the Sponsor , as appropriate , and pro vide a 
written statement to the IRB/EC (if applicable). All applicable clinical investigation documents shall be 
subject to the same retention policy as detailed in Section 11.5  of the CIP.  
 
A Principal Investigator, IRB/EC or regulatory authority may sus pend or prematurely terminate 
participation in the clinical investigation at the investigational site(s) for which they are responsible. The 
investigators will follow the requirements specified in the Clinical Trial Agreement.  
 
If the Sponsor suspends or prematurely terminates the clinical investigation at an individual site in the 
interest of safety, the Sponsor will inform all other Principal Investigators.  
 
If suspension or premature termination occurs, the Sponsor will remain responsible for providing 
resources to fulfill the obligations from the CIP and existing agreements for following the subjects 
enrolled in the clinical investigation, and the Principal Investigator [INVESTIGATOR_403980]/her site, and return patients to their standard medical treatment . 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ADDRESS_509325] implant.  
 
1 - Non-surgical  is defined as  any event occurring > [ADDRESS_509326] implant.  
2 - Major Hemocompatibility Related Adverse Event s include : 
• Stroke  
• Pump Thrombosis (suspected or confirmed)  
• Bleeding (including intracranial bleeds that do not meet the stroke definition)  
• Arterial Peripheral Thromboembolism . 
 
This study assesses  the overall change in the overall incidence of major hemocompatibility related 
adverse events  between the two groups . Additional secondary endpoints will also be evaluated to 
monitor effects on other safety and efficacy measures.   
 
This composite primary endpoint reflects the interrelatedness of hemocompatibility related adverse 
events , providing  an endpoint that will result in  a clear answer to the study’s primary question of whether 
or not anti -platelets are required to maintain the  safety and efficacy p rofile of the HM3. Because the post-
implant clinical course can be widely variable due to clinical responses to adverse events, this composite 
endpoint focuses on the first major hemocompatibility related adverse event to ensure the effect of the 
treatment  arm is reflected in the primary endpoint measure.  Non-composite endpoints or endpoints that 
do not focus on the first event have the possibility of being rendered futile or distorted  by [CONTACT_404031].  Refer to section 8 of th is CIP and the SAP for details.  
4.2 Secondary Endpoint  
As secondary endpoint s: 
• Non-surgical Major Hemorrhagic Events  
• Non-surgical Major Thrombotic Events  
• Survival  
• Stroke Rates,  
• Pump Thrombosis Rates  
• Bleeding Rates, including:  
o Non-surgical Bleeding  
o Moderate Bleeding  
o Severe Bleeding  
o Fatal Bleeding  
o GI Bleeding  
 
will be compared  between the two arms of the study  as detailed in  section 8 of this CIP and the SAP.  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ADDRESS_509327] meet all randomization eligibility requirements 
at randomization. Only randomized subjects will continue to be followed in this study. Subjects not 
meeting randomization eligibility requirements will be considered screen failures and withdrawn from the 
study. Reason(s) for not meeting randomization eligibility requirements will be captured in the study 
EDC. Randomized subjects ongoing without a surgical adverse event, defined as ≤[ADDRESS_509328] Screening 
Patients receiving an LVAD at study sites should be considered for enrollment. All patients evaluated for 
inclusion in the clinical study, including those who provide informed consent and are enrolled , will be 
recorded on the site screening log. Rationale for exclusion from the trial will be recorded. Specifically, reasons may include refusal to cons ent, did not meet eligibility criteria or other specified reasons . To 
monitor for selection bias in enrollment, any patient excluded exclusively due to an investigator mandated antiplatelet therapy (either mandated antiplatelet presence or mandated absence of 
antiplatelets ) will require specific clinical reasons recorded on the screening log.  
 Potential subjects presenting at the clinical sites will be fully informed about the clinical investigation , 
following the established informed consent process (described in Section 5.2.2). Once informed consent 
is obtained, subjects are considered enrolled. Thereafter, all subjects will have required baseline data 
beyond site standard of care captured and US -based patients will have blood drawn for baseline aspi[INVESTIGATOR_403981] (per section 2.4.6) . Subjects who do not meet enrollment or randomization 
criteria will be considered screen failures. 
 Informed Consent 
The Investigator or his/her authorized designee will conduct the informed consent process, as required by [CONTACT_26137]’s IRB/EC. This process will include a verbal discussion with the 
subject on all aspects of the clinical investigation that are relevant to the subject’s decision to participate, 
such as details of clinical investigation procedures, anticipated benefits, and potential risks of clinical 
investigation participation. Subjects must be informed about their right to withdraw from the clinical 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ADDRESS_509329] is otherwise entitled. Withdrawal from the clinical investigation  will not jeopardize their future 
medical care or relationship with the investigator.  
 
During the discussion, the Principal Investigator [INVESTIGATOR_022]/her authorized desig nee will avoid any improper 
influence on the subject and will respect  the subject’s legal rights.  Financial incentives will not be given to 
the subject . The subject shall be provided with the informed consent  form written in a language that is 
understandab le to the subject and has been approved by [CONTACT_16018]’s IRB/EC. The subject shall have 
adequate time to review, ask questions , and consider participation. The Principal Investigator [INVESTIGATOR_022]/her 
authorized designee will make efforts to ensure that the subjec t understands the information provided. If 
the subject agrees to participate, the informed consent  form must be signed and dated by [CONTACT_404032] -specific procedures  
beyon d SOC . The signed original will be filed in the subject’s hospi[INVESTIGATOR_26107], and a copy will 
be provided to the subject.  
 
Failure to obtain informed consent from a subject prior to clinical investigation  enrollment should be 
reported to Sponsor within 5 working days and to the reviewing center’s IRB/EC according to the IRB’s/ 
EC’s reporting requirements.  
 
If, during the clini cal investigation , new information becomes available that can significantly affect a 
subject's future health and medical care, the Principal Investigator [INVESTIGATOR_022]/her authorized designee will 
provide this information to the subject. If relevant, the subject will be asked to confirm their continuing 
informed consent in writing.  
 
In addition, an authorization for use and disclosure of the subject’s protected health information, in 
accordance with the Health Insurance Portability and Accountability Act (HIPAA)  or local equivalent, as 
applicable , must be obtained from the subject. This may be incorporate d into the main ICF or captured 
as a standalone document .   
 
This study will not permit  informed consent via legal ly authorized representatives. Therefore, 
incapacitated individuals, including the mentally handicapped or individuals without legal authority  or 
individuals under the age of [ADDRESS_509330] is found after 
the time of informed consent but prior to randomization to no longer meet any of the inclusion criteria, or 
to meet any of the exclu sion criteria  (randomization eligibility ), the subject will not be randomized and will 
be considered a screen failure and withdrawn from the study.  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ADDRESS_509331] of care (SOC) in accordance with the approved 
indications for use in the country of implant. 
2. Subject will receive the HeartMate [ADDRESS_509332]-implant additional temporary or permanent mechanical circulatory support (MCS) .  
2. Post-implant Investigator mandated antiplatelet therapy for other conditions (including mandated 
presence or absence of antiplatelet agent). 
3. Patients who are nil per os (NPO) post-implant through day 7. 
4. Subjects with a known allergy to acetylsalicylic acid (aspi[INVESTIGATOR_248]). 
5. Participation in any other clinical investigation(s) involving an MCS device, or interventional 
investigation(s) likely to confound study results or affect study outcome. 
6. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological 
conditions that, in the investigator’s opi[INVESTIGATOR_1649], could limit the subject’s ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness 
of the clinical investigation results. 
5.[ADDRESS_509333] is withdrawn, experiences an outcome (transplant, explant, exchange, or death), or completes study follow-up.  Subjects who provide informed consent and are subsequently found to not meet inclusion/exclusion criteria prior to randomization or otherwise do not proceed to randomization will be withdrawn in 
accordance with section 5.5 of this CIP. Subjects who experience a surgical adverse event prior to day 
14 that requires investigator mandated antiplatelet therapy (either presence or absence) will be 
withdrawn and not included in the analysis population . Subjects who expi[INVESTIGATOR_403982] [ADDRESS_509334] shown significant improvement in reduction of pump 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ADDRESS_509335] added relevancy to their treatment 
plan. For this purpose, it is important that Medicare beneficiaries are studied in this trial so  that relevant 
outcomes may be translated more broadly. 
 
To further characterize the  portion of the subjects enrolled in the clinical investigation that display 
characteristics consistent with the Medicare population based on age , the clinical investigation results will 
be analyzed by [CONTACT_654] (< 65 years and ≥ 65 years) to ensure that the outcomes are similar between the 
Medicare and non-Medicare populations. Additional subgroup analyses are detailed in section 8.5. 
 Historically Under-Represented Demographic Subgroups 
The Sponsor intends to implement the FDA's guidance on sex-specific data in medical device clinical 
investigations to ensure adequate representation of women and other traditionally under-represented 
demographic subgroups in this clinical investigation. As noted in the guidance, some barriers to 
participation of women and ethnic minorities in clinical investigations have traditionally been: 
• Lack of understanding about main obstacles to participation of such subgroups in clinical 
research  
• Inclusion/exclusion criteria potentially not needed to define the clinical investigation population 
may unintentionally exclude specific subgroups  
• Under diagnosis of disease etiologies and pathophysiology leading to under referral of 
demographic subgroups 
• Sex differences in disease etiology, which predispose one sex to LVAD therapy 
• Avoidance of specific subgroups by [CONTACT_404033]  
• Family responsibilities limiting women's ability to commit time for follow-up requirements 
 
The Sponsor will take the following steps to ensure adequate representation of women and racial or 
ethnic minorities in this clinical investigation:  
• All patients receiving an LVAD at enrolling sites will be considered for this study and this data will 
be reviewed regularly
• The Sponsor will provide training to investigational site personnel to ensure adequate 
representation of these demographic subgroups  
• As appropriate and necessary, the Sponsor will retrain sites on the importance of recruiting and 
retaining subjects in the clinical investigation if trends in withdrawal or selection bias are noted 
• The Sponsor will approach sites without bias or consideration for specific demographic subgroups  
• The Sponsor will have informed consent materials in alternative languages and will work with 
sites and IRBs/ECs on recruitment materials  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ADDRESS_509336] is 
enrolled  (consented) , but prior to randomization , the subject will be considered a screen failure and 
withdrawn and will not be included in the analysis populations .  
 
Those enrolled (consented) subjects  that meet  all inclusion criteria and no exclusion cri teria post implant 
will be randomized within 2-[ADDRESS_509337] -implant  (the day of implant is day 0) . However, if these s ubjects 
do not meet the randomization eligibility criteria , are not randomized, never start the treatment arm 
regimen,  experience a surgical event ( ≤ [ADDRESS_509338] implant) that requires investigator mandated anti-
platelet therapy  or experience an outcome ≤ [ADDRESS_509339] shall remain in the clinical investigatio n until completion of the required follow -
up period; however, a subject’s participation in any clinical investigation  is voluntary and the subject has 
the right to withdraw at any time without penalty or loss of benefit. Conceivable reasons for 
discontinua tion may include, but not be limited to, the following:  
• Subject outcome including death, transplant, or device explant  or exchange  
• Physician or s ubject voluntary withdrawal  
• Subject lost -to follow -up as described below .  
 
The Sponsor must be notified of the  reason(s) for subject discontinuation. The site will provide this 
information to the Sponsor. Investigators must also report this to their respective IRB/EC as defined by 
[CONTACT_1385]’s procedure(s).  
 
No additional follow –up will be required or data  recorded from subjects once withdrawn from the clinical 
investigation , except for the reason and status at the time of withdrawal (deceased/alive).  Subjects 
withdrawn from the study will cease treatment arm medication and be transitioned to an anticoagulation 
regiment in accordance with site standard of care by [CONTACT_093].  
 
In case of subject withdrawal  of consent , the site should make attempts to schedule the subject for a final 
clinical investigation  visit. At this final follow -up visit, the following will be recorded, with the subject ’s 
permission : 
• Subject status (deceased/alive)  
• Any adverse event details prior to withdrawal of consent  
 
Lost-to-Follow -up 
 
If all attempts at contact[CONTACT_404034], then the subject is considered lost -to-
follow -up Site personnel shall make all reasonable efforts to locate and communicate with the subject 
(and do cument these efforts in the source documents), including the following, at each contact [CONTACT_74056]:  
• A minimum of two telephone calls on different days over the specified follow -up windows to 
contact [CONTACT_404035] n, including date, time and 
initials of site personnel trying to make contact.  
• If these attempts are unsuccessful, a letter (certified , if applicable) should be sent to the subject.  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ZIP_CODE] Rev. F  Page 25 of 81  
 
• If a subject misses one or more non-consecutive follow-up contact [CONTACT_404036], it will be 
considered a missed visit. The subject may then return for subsequent visits.  
 
Note: Telephone contact [CONTACT_150747], non-clinical investigation cardiologist or relative 
without the presence of the subject or indirect documentation obtained via discharge letters will not be 
considered as subject contact.  
 
Sites should attempt to retrieve unused portions of the treatment arm medication in subjects lost-to-
follow, which should be returned to ALMAC Clinical Services per section 2.[ADDRESS_509340] taken or been prescribed (by [CONTACT_105]-study physicians) any of the medications containing aspi[INVESTIGATOR_8427]-like 
compounds and, if so for what duration. Responses will be captured in the EDC. If a subject reports or 
other evidence of incidental aspi[INVESTIGATOR_403983] (i.e. a prescription which the patient confirms from a non-investigator healthcare provider) lasting for a duration of > [ADDRESS_509341]’s clinical course, post-randomization events may result in the investigator mandating 
antiplatelet therapy. The  mandate may consist of the presence of an antiplatelet or the absence of all 
antiplatelets from the patient’s antithrombotic regimen in response to clinical events. These subjects 
should remain in the study for the full 12-month study follow up whenever possible. Investigators may 
cease administration of the treatment arm medication for up to [ADDRESS_509342] reached end of study follow up upon completion of the MRS evaluation. 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 26 of 81  
 
5.7 Number of Subjects  
This study will enroll enough sub jects to randomize 6 28 subjects in the clinical investigation . No site may 
randomize  more than 15% of the total number of randomized subjects  without Sponsor authorization . 
5.[ADDRESS_509343]’s participation is at least [ADDRESS_509344]-
implant . Scheduled visits and data collection for this clinical investigation will occur at Baseline, Implant, 
Randomization, Week 1 ± 3 days, Discharge, Month 1 ± 7 days, Month 3 ± 30, Month 6 ± 30 days, Month 
9 ± 30 days, Month 12 ± 30 days  and, in patients still on the treatment arm medication, follow up will 
continue every 6 months ± [ADDRESS_509345] or investigator will be considered a protocol  
deviation.  Sites should address any questions related to potential unblinding to the Sponsor.  
6.3 Study Activities and Procedures  
The assessments in table 2 will occur throughout the study . 
Table 2 – Schedule of Assessments  
 Assessment  
Baseline  
Implant  
Randomization  
Discharge  
Week 1  
(± 3 days)  
Month 11 
(± 7 days)  
Month 31 
(± 30 days)  
Month 61 
(± 30 days)  
Month 91 
(± 30 Days)  
Month 121 
(± 30 days)  
Every 6 months ± 
60 days thereafter  
As Occurs/ 
Unscheduled  
Inclusion/ Exclusion  X  X          
Informed Consent  X            
Demographics  X            
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 27 of 81  
 
 Assessment  
Baseline  
Implant  
Randomization  
Discharge  
Week 1  
(± 3 days)  
Month 11 
(± 7 days)  
Month 31 
(± 30 days)  
Month 61 
(± 30 days)  
Month 91 
(± 30 Days)  
Month 121 
(± 30 days)  
Every 6 months ± 
60 days thereafter  
As Occurs/ 
Unscheduled  
General and Cardiac Medical History  X            
Coagulation Assessment  X4            
Right Heart Catheterization   X2            X4 
Modified Rankin Score (MRS)  X           X 
Incidental Use of Aspi[INVESTIGATOR_403966]  X   X X X X X X X X  
Vital Signs  X   X X X X X X X  X 
Laboratory Assessments   X3    X X X X X X   X4 
Anticoagulation/Antiplatelet Medications Log  X X  X X X X X X X  X9 X 
Echocardiogram   X2     X4  X4  X4  X4  X4  X4   X5 
Other Medications X     X X X X X  X 
Sample for Core Lab (ASA response, US only)  X      X X  X   
QOL and Functional Capacity  X      X X  X   
Implant Data   X           X6 
Enrollment   X7            
Randomization    X          
Pump Parameters   X   X X X X X X   X5 
Bottle Requisition via WebEZ    X    X X X X X8 X 
Bottle Dispensing /Return  Log   X    X X X X X8 X 
Return Used Bottle to ALMAC for Accountability        X X X X X8 X 
Initial Discharge Data     X         
Cardiac Arrhythmias Assessment (e.g. EGM, EKG)  X    X X X X X X  X 
Subject Status    X X X X X X X X8  
INR & LDH Log  X   X X X X X X X  X 
Death             X 
Withdrawal (early termination)             X 
Transition to Open Label             X 
Hospi[INVESTIGATOR_602]             X 
Adverse Events             X 
Device Deficiencies             X 
Operative Procedures  (excluding primary implant)             X 
1 For follow -up visit scheduling, one month = [ADDRESS_509346] is considered enrolled upon signing of the informed consent form . 
8 Subjects on the treatment arm medication will be followed every six months after the 12 -month vis it. Safety monitoring 
including adverse events, outcomes and device deficiencies and other associated “as occurs” procedures will be collected  
[ADDRESS_509347] udy will be conducted in accordance with the CIP. All parties participating in the 
implementation of the study will be qualified to perform their designated tasks by [CONTACT_8640], training, and 
experience. Applicable documentation will be maintained.  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 28 of 81  
 
No study  activities may begin until the site has received written Sponsor approval. Copi[INVESTIGATOR_403984]/or the relevant regulatory authorities, as well as all required regulatory 
documents must be received by [CONTACT_404037] l be given.  
6.4 Baseline  
The baseline assessments in table 3 will be performed .  
 
Table 3 – Baseline Data Collection  
Study Activity  Data Collection  
Informed Consent  Informed consent details  
Inclusion/Exclusion  Subject’s eligibility details  
Demographics  Age, height, gender, ethnicity  (except where prohibited by [CONTACT_5151]) , race  (except 
where prohibited by [CONTACT_5151]) , blood type, INTERMACS profile, and NYHA clas s 
General and Cardiac 
Medical History  Etiology of HF, duration of HF, therapeutic intent  (BTT /BTC /DT), arrhythmias, 
prosthetic valve(s), history of stroke, diabetes, smoking, history of bleeding ( diverticular 
disease , diagnosed arteriovenous malformations ( AVMs ), GI ulcer(s), anemia  and/or  
erythropoietin treatment ), aortic stenosis, hypertension, history of MI, peripheral 
thromboembolism, coronary stents, CABG, substance abuse (drug/alcohol), 
drug/radiation toxicity, peripheral vascular disease, carotid artery disease, cardiac 
rhythm management device, intra -aortic balloon pump, other pre -implant circulatory 
support, CardioMEMS, and HIV  status  
Modified Rankin Score  Modified Rankin Score (MRS)  
Vital Signs  Weight, blood pressure, and heart rate  
Anticoagulation/Antiplatelet 
Medications  Vitamin K antagonist (e. g. warfarin, fluindione, phenprocoumon , etc.), clopi[INVESTIGATOR_7745], 
dipyridamole, other anticoagulation agents, other vitamin K antagonists, direct 
thrombin inhibitors, etc. (including treatment arm medication ) 
All new medications started, or current medications stopped during the follow -up period 
must be rec orded. All dose changes (including IV titrations  as total daily dose ) during 
the follow -up period must be recorded with the exclusion of vitamin K antagonist . Only 
the type,  start and stop dates , and target INR will be collected for vitamin K antagonist.  
Other  Medications  ACE inhibitors, inotropes, ARBs, beta blockers, antiarrhythmics, statins, nitrates, 
allopurinol, aldosterone blockers, antibiotics, diuretics, insulin and antidiabetic 
medications , and other cardiovascular medications  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 29 of 81  
 
Study Activity  Data Collection  
Laboratory Assessments1 Hemoglobin ( Hgb), Hematocrit  (Hct), White Blood Cell Count  (WBC ), Platelets ( PLT), 
Creatinine (Cr), Estimated Glomerular Filtration Rate (eGFR), LDH and INR , liver 
function tests (AST , ALT, total bilirubin, albumin, pre -albumin), blood urea nitrogen 
(BUN)  
Collected only if  SOC:  Activated Partial Thromboplastin Time  (aPTT ), Partial 
Thromboplastin Time ( PTT), Plasma free Hgb (PHgb), D -Dimers, P Selectin , and 
fibrinogen . For diabetic patients:  HbA1c,  brain natriuretic peptide (BNP) or N -terminal 
pro-BNP (NT -pro-BNP)  and fasting glucose  
Coagulation Assessment2 Collected only if prior testing performed or  SOC:  Tests may include but are not limited 
to HIT, protein C deficiency, protein S deficiency, antithrombin deficiency, plasminogen 
deficiency, lupus anticoagulant, factor V Leiden, prothrombin G20210A mutation, and 
primary antiphospholipid syndrome  
Right Hear t Catheterization2 Central venous pressure (CVP) or right atrial pressure (RAP), systolic, diastolic and 
mean pulmonary artery pressure (PAS, PAD, PAM), pulmonary capi[INVESTIGATOR_17931] (PCWP), cardiac output (CO), and cardiac index  (CI) 
Echocardiogram2 Type of assessment, LVEF, LVEDD, LVESD, AI, MR, TR, PR, including severity and/or 
grade, and presence of LV or LA thrombus, and aortic valve opening ratio  
QOL and Functional 
Capacity  EQ-5D-5L, [ADDRESS_509348] (if subject is able, reason must be provided if not 
performed), NYHA Class, INTERMACS Profile  
[ADDRESS_509349]’s HM3 implant  procedure.  
Table 4 – Implant Procedure Data Collection  
Study Activity  Data Collection  
HM3 System Information  VAD serial number, reference number and date of implant of entire implanted 
system  
Implant Data  Presence of intracardiac (LA or LV)  thrombus, concurrent  procedures, Factor VII 
administration, vitamin K administration, anti-fibrinolytic administration,  pump 
position, transfusions (whole blood, packed red blood cells [PRBC], fresh frozen 
plasma [FFP], platelets, cryoprecipi[INVESTIGATOR_047], Cell Saver), cardiopulmonary  by[CONTACT_6476] 
(CPB) time, and total implant  time, procedure initiation/completion time , 
additional post -implant MCS  
Pump Parameters  Pump Speed, Pump Flow, Pulsatility Index, and Pump Power  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ADDRESS_509350] provided informed consent , been e nrolled , been implanted with the HM3 and 
subsequently met all inclusion and no exclusion criteria (randomization eligibility ) will be randomized  in 
the study . Randomization will be performed through ALMAC Clinical’s WebEZ system. Subjects will be 
randomize d 1:1, by [CONTACT_3725] , and  in permuted blocks of 4. Prior to randomizing a patient in WebEZ, patients 
will have been  initialized in the Sponsor’s EDC portal upon enrollment and  obtain ed a subject ID number, 
which will also be used as the patient identifier in the WebEZ system. Subjects should begin taking the 
treatment arm medication within [ADDRESS_509351] status will be recorded along 
with anticoagu lation/antiplatelet medications, LDH, and INR logs . 
6.8 Scheduled Follow -up for All Subjects  
The required assessments  (detailed in tables 2 and 6), follow -up schedule, and associated visit windows 
(table 5) are generally aligned with SOC LVAD patient follow up and MCS registry  data collection . All 
follow -up visits are based on the  initial implant date. The windows for each follow -up visit are as follows:  
Table 5 – Follow -up Visit Windows  
Randomization  Visit 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6 Visit 7+  
2-7 days  Week 1  
± 3 days  Month 1  
± 7 days  Month 3  
± 30 days Month 6  
± 30 days Month 9  
± 30 days Month 12  
± 30 days  Every 6 M onths 
± [ADDRESS_509352]’s consent, be requested and reviewed for potential adverse events.  
 
For subjects not on the treatment arm medication, the completion of the Month 12 visit  will signify 
completion of the study,  with the exception of some lab results that may be received after the visit has 
occurred, no other assessments or study related activities may be performed after the final visit has 
occurred, even  if later assessments are performed within the acceptable window. Month 12 assessments  
(including required laboratory assessments  blood draws ) not collected by [CONTACT_404038] s.  
 
Subjects on the treatment arm medication will continue to be followed every [ADDRESS_509353] be collected by [CONTACT_404039], 
as outlined above.  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 31 of 81  
 
Table 6 – Scheduled Follow -Up Visit Data Collection  through [ADDRESS_509354] is ongoing on HM3 LVAD support, if not, what was the 
outcome the patient experienced  
Vital Signs  Weight, blood pressure  and method of blood pressure measurement  
Pump Parameters  Pump Speed, Pump Flow, Pulsatility Index, and Pump Power  
Cardiac Arrhythmias  Atrial (fibrillation/flutter),  ventricular  (fibrillation/VT), and  treatment   
Anticoagulation  / Antiplatelet  
Medications  All changes made during the follow -up period  
 
All new medications started, or current medications stopped during the follow -up 
period must be recorded. All dose changes (including IV titrations) during the 
follow -up period must be recorded with the exclusion of vitamin K antagonist . Only 
the type,  start and stop dates , and target INR  will be collected for vitamin K 
antagonist . 
Other  Medications  ACE inhibitors, inotropes, ARBs, beta blockers, antiarrhythmics, statins, nitrates, 
allopurinol, aldosterone blockers, antibiotics, diuretics, insulin and anti diabetic 
medications, and other cardiovascular medications  
Treatment Arm Bottle 
Dispensing /Return  Log All bottles dispensed during the follow -up period  (Month 3, 6 and 9 follow -up visits 
only), including replacement bottles that are dispensed outside of t he follow -up 
schedule , bottle status (lost by [CONTACT_4676], returned to ALMAC) and shippi[INVESTIGATOR_180987].  
All bottles and unused doses must be returned to ALMAC Clinical within [ADDRESS_509355].  
Laboratory Assessments  
 Hemoglobin ( Hgb), Hematocrit  (Hct), White Blood Cell Count  (WBC ), Platelets 
(PLT), Creatinine (Cr), Estimated Glomerular Filtration Rate (eGFR) , liver function 
tests (AST , ALT, total bilirubin, albumin, pre -albumin), blood urea nitrogen (BUN)  
 
Log Data (all measurements du ring the follow up period will be collected with, at a 
minimum, 1 reading within each follow up window): LDH and INR.  
 
Collected only if  SOC:  Activated Partial Thromboplastin Time  (aPTT ), Partial 
Thromboplastin Time ( PTT), Plasma free Hgb (PHgb), D -Dimers, P Selectin , and 
fibrinogen . For diabetic patients:  HbA1c, brain natriuretic peptide (BNP) or N -
terminal pro -BNP (NT -pro-BNP) and fasting glucose  
Note : To protect blinding of the study, p latelet function testing (including ASA 
resistance testing) will not be performed while patient is on the treatment arm 
medication , except as outlined in section 2.4.6 .  
1 Echocardiogram  LVEF, LVEDD, LVESD, AI, MR, TR, PR, including severity and/or grade , and 
presence of LV or LA thrombus, and aortic valve opening ratio  
QOL and Functional Capacity  EQ-5D-5L, [ADDRESS_509356], NYHA Class, INTERMACS Profile  
1 If collected per SOC.   
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ADDRESS_509357] status (including death, withdrawal, or transplant) along with adverse events and device deficiencies will be collected along with additional supportive data should 
adverse events or device deficiencies occur. If a patient’s clinical course after [ADDRESS_509358] reached the end of study follow 
up unless the transition to open label is due to a stroke, in which case the patient should be followed for an additional 60 -days to capture the MRS score. The clinical reason for transition to open-label will be 
captured. Subjects transitioned to open label prior to 12 months of follow up should be followed to their 
12-month follow up.  
6.9 Unscheduled Visits 
 Adverse Events 
For additional details regarding adverse e vents, refer to section 7. Data related to adverse events will be 
collected as they occur. Depending on the type of adverse event, relevant data will be collected.  
[IP_ADDRESS]  Neurologic Adverse Events 
Modified Rankin Scores ( MRS ) scores will be captured at: 
• Baseline, 
• The time of any stroke or potential stroke events, and  
• 60-days after any stroke or potential stroke events to adjudicate the severity of the event.  
MRS will be determined by [CONTACT_37702], defined as an independent, trained, and certified 
clinician. Event severity will be determined based on M RS, specifically MRS > 3 as disabling versus 
MRS ≤ [ADDRESS_509359], if the 
operation is unknown to the implanting site (i.e. occurring at another facility), during the next follow-up 
visit. For pump exchang es, additional implant data will be collected, including exchange status and pump 
exchange type.  
 Hospi[INVESTIGATOR_403985], excluding the primary implant hospi[INVESTIGATOR_059], with associated reasons will be captured during the follow-up period for all subjects. While hospi[INVESTIGATOR_057], the follow-up visit assessments 
will continue to be performed according to the follow-up schedule. Hospi[INVESTIGATOR_403986], at the 
latest, if the hospi[INVESTIGATOR_403987] (i.e. occurring at another facility), during the 
next follow-up visit.  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ADDRESS_509360] has transition ed to open -label  (e.g. due to 
pump thrombosis the investigator believes the patient should remain on open-label aspi[INVESTIGATOR_119457]).  
 If a subject receives a pump exchange during the follow-up period, this event will be considered a device explant outcome and data will be collected on the pump exchange procedure but not after. If a subject 
has a device explanted for suspected or confirmed pump thrombosis, the pump will be returned to the 
Sponsor for analysis. Standard commercial processes will be used for pump return. 
6.[ADDRESS_509361]’s randomization 
throughout the study follow up. Additionally, sponsor personnel , and the CEC will not have access to 
patient or population blinding information. The blind of the study will only be broken once the study 
follow-up is completed, and all adverse events have been adjudicated. Questions related to unblinding 
should be directed to the Sponsor.
6.11 Patient Reported Outcome (PRO) Measure 
The Coordinator or designee will administer patient-reported outcome questionnaires. It is important the 
subject understands the meaning of all words and instructions in the questionnaires. The subject should 
be instructed to ask any questions about the questionnaires if further explanation is needed. Once the questionnaires are completed, the Coordinator or designee will review for completeness to verify that all questions have been answered according to the directions provided.  
 The following PRO measures will be collected according to the requirements of the questionnaire and 
this CIP. 
• EQ-5D -5L - EuroQOL 
 The EQ-5D-5L is a standardized measure of health status developed by [CONTACT_404040] a simple, generic measure of health for clinical and economic appraisal. Applicable to a wide 
range of health conditions and treatments, it provides a simple descriptive profile and a single index 
value for health status that can be used in the clinical and economic evaluation of healthcare as well as in population health surveys. The questionnaire will take approximately two minutes to complete.   The EQ-5D-5L consists of two components – the EQ-5D-5L descriptive system and the EQ Visual 
Analogue scale (VAS). For the descriptive system, five dimensions are measured (mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression). Each dimen sion has five levels: 1=none, 
2=slight, 3=moderate, 4=severe, and 5=extreme. The respondent indicates his or her health state by [CONTACT_404041]. The VAS is 
scored from 0 (worst health) to 100 (best health).  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ADDRESS_509362] definitions and reporting timelines to be 
used and adhered to by [CONTACT_473].  
7.1 Definition 
 Adverse Event 
An adverse event (AE) is any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory findings) in subjects. 
 Serious Adverse Event 
If the AE meets any of the criteria below, it is regarded as a serious adverse event (SAE).  
a) Led to a death,  
b) Led to a serious deterioration in health of the subject, that either resulted in  
1. a life-threatening illness or injury, or 
2. a permanent impairment of a body structure or a body function, or 
3. in-patient hospi[INVESTIGATOR_1081], or  
4. medical or surgical intervention to prevent life threatening illness or injury or permanent 
impairment to a body structure or a body function. 
5. chronic disease  
c) Led to fetal distress, fetal death or a congenital abnormality or birth defect.  
 
Note: A planned hospi[INVESTIGATOR_5912]-existing condition, or a procedure required by [CONTACT_10396], without a 
serious deterioration in health, is not considered to be an SAE.
 Device Deficiency 
Device deficiency is defined as an inadequacy of a medical device relate d to its identity, quality, 
durability, reliability, safety or performance, such as malfunction, misuse or use error and inadequate labeling. This includes the failure of the device to meet its performance specifications or otherwise perform as intended. Note: Performance specifications include all claims made in the labeling of the device. 
7.2 Device Relationship 
Determination of whether there is a reasonable possibility that the HM3 LVAS caused or contributed to 
an AE is to be determined by [CONTACT_737] a nd recorded on the appropriate CRF form. Determination 
should be based on assessment of temporal relationships, evidence of alternative etiology, 
medical/biologic plausibility, and patient condition (pre-existing condition). 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ADDRESS_509363] ([LOCATION_003]DE) 
Unanticipated Serious adverse device effect ([LOCATION_003]DE) refers to any serious adverse effect on health or 
safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of 
subjects. 
7.3 Adverse Event and Device Deficiency/Device Malfunction Reporting 
 Adverse Event Reporting 
Safety surveillance and reporting starts as soon as the patient is enrolled in the clinical investigation. 
Adverse events occurring prior t o randomization which disqualify a patient for randomization, but occur 
after consent, will be captured in the EDC and, if necessary, should be reported to the sponsor through 
standard commercial practices. Safety surveillance and reporting will continue until the last follow-up visit has been performed, the subject is deceased, the subject concludes participation in the clinical investigation or the subject withdraws from the clinical investigation. All adverse event , deaths , and 
device deficiency data will be collected throughout the time period defined above and will be reported to the Sponsor on a CRF. Additional information about an adverse event should be updated within the 
appropriate CRF. An offline form will be made available to allow the investigator to report SAEs in the 
event the entry cannot be made in the EDC . This offline form can be submitted by [CONTACT_404042] @abbott.com . This does not replace the EDC reporting system. All information must still 
be entered in the EDC system as soon as feasible. 
 Unchanged, chronic, non-worsening or pre-existing conditions are not AEs and should not be reported.  
 Abnormal laboratory values will not be considered AEs unless:  
• the investigator determined that the value is clinically significant,  
• the abnormal lab value required intervention, or  
• the abnormal lab value required subject withdrawal from the clinical investigation, or  
• the abnormal lab value meets the definition of a n adverse event. 
 
All adverse events will be collected on each subject through out the follow up period – until the subject 
reaches an outcome or withdraws or until the study ends . Causes of death will be captured for all 
subjects who expi[INVESTIGATOR_403988] u p. 
 
SAE Reporting 
The investigator should report all SAEs to the Sponsor as soon as possible but no later than outlined 
below.  
 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ADDRESS_509364] be reported to the Sponsor  no later than 3 cale ndar days from the 
day the site personnel became aware of the event or as per the investigative 
site’s local requirements, if the requirement is more stringent than those outlined. 
 The date the site staff became aware the event met the criteria of an SAE must be recorded in the 
source document. The Investigator will further report the SAE to the local IRB/EC according to the institution’s IRB/EC reporting requirements. 
 Unanticipated Serious Adverse Device Effect Reporting to Sponsor and IRB/EC 
The Sponsor requires the Investigator to report any [LOCATION_003]DE to the Sponsor within 3 calendar days of the 
investigator’s knowledge of the event, unless local requirements are more stringent, and to the IRB/EC 
per IRB/EC requirements.  
 Device Deficiency Reporting 
All device deficiencies/malfunctions should be reported on the appropriate CRF form.  
 The investigator should report all device deficiencies/malfunctions to the Sponsor as soon as possible but no later than outlined below.  
 
Clinical Sites Reporting timelines 
All Sites Device deficiencies/malfunctions must be reported to the Sponsor no later 
than 3 calendar days from the day the site personnel became aware of the event or as per the investigative site’s local requirements, if the requirement is more stringent than those outlined . 
 Device deficiencies/malfunctions should be reported to the IRB/EC per the investigative site’s local requirements.  
An offline form will be made available to allow the investigator to report device deficiencies/malfunctions 
in the event that the entry cannot be m ade in the EDC system. This offline form can be submitted by 
[CONTACT_404043] @abbott.com. This does not replace the EDC reporting system. All information 
must still be entered in the EDC system as soon as feasible.  
 Adverse Event Reporting to Country Regulatory Authorities by [CONTACT_404044]/malfunctions to the country regulatory 
authority, per local requirements.  
 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ZIP_CODE] Rev. F  Page 37 of 81  
 
Note: Reportable device deficiencies/malfunctions include device deficiencies/malfunctions that might 
have led to an SAE if a) suitable action had not been taken or b) intervention had not been made or c) if 
circumstances had been less fortunate. These are handled under the SAE reporting system. 
 
Clinical investigation SAEs and device deficiencies/malfunctions reportable per MedDEV 2.7/3 
regulations will be submitted to European Competent Authorities by [CONTACT_1034]’s Clinical Safety Group. 
The S ponsor’s Clinical Safety Group’s contact [CONTACT_404045] I.  
8.0 STATISTICAL CONSIDERATIONS 
The following section describes the statistical methods for the clinical investigation. Additional details on 
statistical analyses, including justification of clinical investigation design, sensitivity analyses, poolability 
analyses, subgroup analyses and analysis of descriptive endpoints, will be maintained in a separate 
Statistical Analysis Plan (SAP). 
8.1 Analysis Populations 
 Modified Intention to Treat Population (mITT) 
The Modified Intention to Treat Population (mITT) will include all randomized subjects with the following 
exception: 
 
1. Subjects who experience a surgical adverse event, defined as ≤[ADDRESS_509365]-implant, 
requiring investigator mandated antiplatelet therapy 
2. Subjects who expi[INVESTIGATOR_1312], are transplanted, or withdrawn within 14 days of implant 
 
Non-surgically related major hemocompatibility related adverse events will only be analyzed up to the 
transition to open label.  Subjects will be analyzed according to the treatment arm assigned at 
randomization . The mITT population will be used for all analyses unless noted differently in one 
sensitivity analysis. 
 Intent -To-Treat (ITT) Population 
The ITT population will consist of all subjects randomized. Subjects will be analyzed according to the 
treatment arm assigned at randomization. The ITT population will only be used for one sensitivity 
analysis of the primary endpoint. 
8.2 Statistical Analyses  
 Primary Endpoint Hypothesis 
The primary endpoint hypothesis is formally expressed as: 
H0: πplacebo  ≤ π aspi[INVESTIGATOR_248] - ∆ 
Ha: πplacebo  > πaspi[INVESTIGATOR_248] - ∆ 
 
where π placebo and π aspi[INVESTIGATOR_403989] ∆ is the non-inferiority margin fixed at 10%. Justification of 
the non -inferiority margin is included in the SAP.  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ZIP_CODE] Rev. F  Page 38 of 81  
 
 Primary Endpoint Analyses Methodology 
The primary endpoint composite success rate will be calculated for each treatment arm based on the 
number of subjects who successfully meet the primary endpoint divided by [CONTACT_404046]. The placebo arm will be considered non-inferior to the aspi[INVESTIGATOR_403990]-sided 9 7.5% confidence limit of the risk difference in the composite success 
between treatment arms (Placebo-arm minus Aspi[INVESTIGATOR_248]-arm) is greater than the non-inferiority margin (-
10%).  
 Secondary Endpoint Analyses 
The secondary endpoints will be analyzed using the mITT Populations. Details of the secondary endpoint 
analyses are provided in the SAP. The secondary endpoints are: 
• Non-surgical Major Hemorrhagic Events 
• Non-surgical Major Thrombotic Events 
• Survival 
• Stroke Rates,  
• Pump Thrombosis Rates 
• Bleeding Rates, including: 
o Non-surgical Bleeding
o Moderate Bleeding 
o Severe Bleeding 
o Fatal Bleeding 
o GI Blee ding 
 Descriptive Endpoints 
Hemocompatibility Score: The Hemocompatibility Score (HCS) is a tiered hierarchal score that weighs 
each hemocompatibility related adverse event by [CONTACT_404047]4. The HCS will be 
calculated for each subject in mITT Population and summarized for the treatment group as a median 
score and range.  
 
Rehospi[INVESTIGATOR_602]: The rehospi[INVESTIGATOR_403991] a rehospi[INVESTIGATOR_059], for any cause, after randomization and initiation of the study treatment, 
divided by [CONTACT_404048]. The number of rehospi[INVESTIGATOR_403992]. Details of the analysis are presented 
in the SAP .  
 
Economic Cost : Health resource utilization will be assessed by [CONTACT_404049][INVESTIGATOR_057] (categorized 
by [CONTACT_404050]) between groups in the mITT Population with cost implications 
compared based on cost of hospi[INVESTIGATOR_059], per day hospi[INVESTIGATOR_057]. 
8.3 Sample Size Calculation and Assumptions 
Results from the MOMENTUM 3 trial were used to derive a point estimate of 71% survival to 1 year free 
of any major hemocompatibility related adverse events in the aspi[INVESTIGATOR_403993]. It is assumed that in 
the absence of aspi[INVESTIGATOR_248] a 2% improvement in the composite endpoint will be noted, mainly due to the 
reduction of bleeding complications without a change in thromboembolic complications. Based on these 
assumptions 2 20 patients will need to be randomized in each arm (4 40 total) to achieve 80% power to 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 39 of 81  
 
prove that the placebo group is non -inferior to the aspi[INVESTIGATOR_403994] a non -inferiority margin of 10% 
with the Farrington -Manning risk difference approach to non -inferiority at a one -sided alpha = 0.0 25. To 
account for an expected 30% dropout rate associated w ith events occurring [ADDRESS_509366] reached a primary endpoint  and the study has been unblinded .   
8.5 Subgroup Analysis  
A subgroup analysis will be performed to examine the consistency of results for the primary endpoint 
across specific populations. Analysis will be performed using Fisher’s exact test. No subgroup specific 
labeling claims are intended for the primary endpoi nt and no adjustment will be made for multiplicity. 
Subgroups to be examined include, but are not limited to, gender , age (stratified by [CONTACT_404051]) , age 
(less than 65 vs 65 and greater ), race, INTERMACS profile (INTERMACS 1 -2 vs INTERMACS 3+) , TTR  
and sur gical implant method.  If home monitoring of anticoagulation is used in some sites but not others, 
a subgroup analysis based on home monitoring will be conducted.  
8.[ADDRESS_509367] anned for this study . 
8.10 Statistical Criteria for Termination  
There are no statistical criteria for termination of this clinical investigation.  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 40 of 81  
 
8.11 Success Criteria  
The trial will be considered successful if null hypothesis of the primary endpoint is rejected ( i.e. the 
placebo group is non -inferior to the aspi[INVESTIGATOR_34209]).  
8.[ADDRESS_509368] ACCESS TO SOURCE DATA/DOCUMENTS  
The investigator/institution will permit direct access to source data/documents for the purpose of 
performing clinical investigation -related monitoring, audits, IRB/EC review and regulato ry inspections.  
 
Subjects providing informed consent are agreeing to allow clinical investigation  monitors or regulatory 
authorities including foreign countries to review, in confidence, any records identifying the subjects in this 
clinical investigation . This information may be shared with regulatory agencies; however  the Sponsor 
undertakes not to release the subject's personal and private information  otherwise.  
10.[ADDRESS_509369] investigators qualified by [CONTACT_404052] . Sites will be selected based upon review of a recen t site assessment, if applicable, and the 
qualificatio ns of the investigators who will participate in the clinical investigation . 
10.2 Clinical Investigation Finances and Agreements  
The clinical investigation will be financed by [CONTACT_69735]. Investigational sites wi ll be compensated by [CONTACT_404053].  
10.3 CIP Amendments  
Approved CIP amendments will be provided to the Investigators by [CONTACT_404054]. The Principal Investigator [INVESTIGATOR_179168]/EC or equivalent committee of 
the CIP amendment (administrative changes) or obtaining IRB’s/EC’s approval of the CIP amendment 
(changes in subject care or safet y), according to the instructions provided by [CONTACT_404055].   
 
Acknowledgement/approval by [CONTACT_1201]/EC of the CIP amendment must be documented in writing prior to 
implementation of the CIP amendment. Copi[INVESTIGATOR_403995] a lso be provided to the 
Sponsor.  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ZIP_CODE] Rev. F  Page 41 of 81  
 
10.4 Training 
Site Training 
All Investigators and clinical investigation personnel are required to attend Sponsor training sessions, 
which may be conducted at an Investigator's meeting, a site initiation visit, or other appropriate training 
sessions. Over-the -phone or self-training may take place as required. Training of Investigators and 
clinical investigation personnel will include, but is not limited to, the CIP requirements, electronic case 
report form completion, WebEZ functionality, and clinical investigation personnel responsibilities. All 
Investigators and clinical investigation personnel that are trained must sign a training log (or an equivalent) upon completion of the training. Prior to signing the training log, Investigators and clinical investigation personnel must not perform any CIP-related activities that are not considered standard of care at the site.  
10.5 Monitoring  
Sponsor and/or designee will monitor the clinical investigation over its duration according to the CIP-
specific monitoring plan which will include the planned extent of source data verification.  
 Prior to initiating any procedure, the Sponsor monitor (or delegate) will ensure that the following criteria are met:   
• The investigator understands and accepts the obligation to conduct the clinical investigation 
according to the CIP and applicable regulations and has  signed the Investigator Agreement or the 
Clinical Trial Agreement, as applicable .  
• The Investigator and his/her staff should have sufficient time and facilities to conduct the clinical 
investigation and should have access to an adequate number of appropriate subjects to conduct 
the clinical investigation .  
• Source documentation (including original medical records) must be available to substantiate 
proper informed consent procedures, adherence to CIP procedures, adequate reporting and 
follow-up of adverse events, accuracy of data collected on case report forms, and device information.  
• The Investigator/site will permit access to such records. A monitoring visit sign-in log will be 
maintained at the site. The Investigator will agree to dedicate an adequate amo unt of time to the 
monitoring process. The Investigator and/or research coordinator will be available for monitoring 
visits. It is expected that the Investigator will provide the monitor with a suitable working 
environment for review of clinical investigat ion-related documents. 
10.[ADDRESS_509370]. In that event, the Investigator will notify Sponsor immediately 
by [CONTACT_404056].  
 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ADDRESS_509371] be reported to the 
Sponsor  using the Deviation CRF . The occurrence of protocol deviations will be monitored by [CONTACT_404057]. Investigators will inform their IRB/EC or equivalent committee of all CIP 
deviations in accordance with their specific IRB/EC or equivalent committee reporting policies and 
proced ures.  
 
In the event of repeated non -compliance, as determined by [CONTACT_1034], a Sponsor’s monitor or 
company representative will attempt to secure compliance by [CONTACT_10980] (and not 
limited to):  
• Visiting the investigator and/or delegate  
• Telephoning the investigator and/or delegate  
• Corresponding with the investigator and/or delegate  
 
Repeated non -compliance with the signed agreement, the CIP or any other conditions of the clinical 
investigation  may result in further escalation in accordanc e with the Sponsor’s written procedures , 
including securing compliance or, at its sole discretion , Sponsor may terminate the investigator's 
participation in the clinical investigation .  
 
Deviations from the protocol include, but are not  limited to :  
• withdr awal of the treatment arm antithrombotic regimen without clinical reasons  
• additional antiplatelet medications added to the treatment arm antithrombotic regimen  
• enrollment or randomization of patients who do not meet eligibility requirements  
• informed cons ent deviations, except inadvertent incorrect dating.  
10.[ADDRESS_509372] audits in accordance with the audit plan and the operating procedures.  
2. Individual engaged in auditing (hereinafter referred to as "auditor") shall be different than those in 
charge of medical device development or monitoring.  
3. The auditor shall prepare an audit report documenting the matters confirmed in the audit to certify 
and verify that the audit has been conducted, and submit the m to the Sponsor.  
 
In the event that an investigator is contact[CONTACT_426] a Regulatory Agency in relation to this clinical 
investigation, the Investigator will notify Sponsor immediately. The Investigator and Research 
Coordinator must be available to respond to  reasonable requests and audit queries made during the 
audit process. The Investigator must provide Sponsor with copi[INVESTIGATOR_403996] (e.g., Form FDA 483, Inspectional Observations, W arning 
Letters, Inspection Reports, etc.). Sponsor may provide any needed assistance in responding to 
regulatory audits.  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott 
Template: [ADDRESS_509373] (DSMB), to review operational issues that may arise and warrant a CIP amendment or other corrective action and to determine policy regarding any publications arising from data generated from the performance of the clinical investigation. The Steering Committee or designee will determine policy and strategies regarding 
individual presentations and/or publications arising from clinical investigation generated data. The 
committee will also review all external requests for accessing clinical investigation-related data and 
strategies aligning with the Sponsor’s presentation and publication team expectations. The Sponsor will align with the committee to ensure the Sponsor’s applicable policies and Standard Operating Procedures 
are followed. 
Data Safety Monitoring Board (DSMB) 
The Data Safety Monitoring Board (DSMB) is an independent multidisciplinary group restricted to 
individuals free of apparent significant conflicts of interest. The source of these conflicts may be financial, scientific, or regulatory in nature. The DSMB is typi[INVESTIGATOR_403997] a biostatistician . The DSMB will meet within 3 
months of study initiation for protocol/study training and to discuss oversight rules including first data 
review point, recurring data review points, and formal rules for recommending study cessation. Formal 
rules for recommending study cessation will be determined by [CONTACT_404058]. 
The DSMB will have access to unblinded datasets, so they may properly assess any safety signal that may arise during the conduct of the study.  The DSMB will serve in an advisory role to the Sponsor to ensure safety by [CONTACT_404059], as well as the continuing validity and scientific merit of the clinical investigation. The composition , frequency of the meetings and the statistical 
monitoring guidelines will be described in detail in the DSMB charter. 
 The DSMB may consider a recommendation for modifications or termination of the clinical investigation 
based on any perceived safety concerns regardless of statistical significance. The recommendations of 
the DSMB are not binding, and all final decisions related to clinical investigations modifications rest with the Sponsor in consultation with the study Steering Committee .  
Clinical Events Committee (CEC) 
The Clinical Events Committee (CEC) is an independent adjudication body comprised of qualified 
physicians who are not participants in the clinical investigation . The CEC will remain blinded to the 
subjects’ treatment arm assignments . The CEC will review and adjudicate pre-specified events reported 
by [CONTACT_404060]. The CEC will adjudicate all deaths, neurologic 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ADDRESS_509374] KEEPI[INVESTIGATOR_403998]/or its affiliates will maintain  documentation of the systems and procedures used in data 
collection for the duration of the clinical investigation .  
 
CRF data collection will be performed through a secure web portal and only authorized personnel wi ll 
access the Electronic Data Capture (EDC) system using a unique username [CONTACT_26160], 
review or correct data. Passwords and electronic signatures will be strictly confidential.   
 
The data will be subjected to consistency and validation checks within the EDC system and 
supplemental review by [CONTACT_3433] e Sponsor.  
 
At the conclusion of the clinical investigation, completed CRF images with the date -and-time stamped 
electronic audit trail indicating the user, the data entered, and any reason for change (if applicable) will 
be provided to the investigationa l sites , if requested .  
 
For the duration of the clinical investigation, the Investigator will maintain complete and accurate 
documentation including, but not limited to, medical records, clinical investigation progress records, 
laboratory reports, CRFs, s igned ICFs, correspondence with the IRB/EC and clinical investigation 
monitor/Sponsor, adverse event reports, and information regarding subject discontinuation or completion 
of the clinical investigation.  
11.1 Protection of Personally Identifiable Information  
The Sponsor respects and protects personally identifiable information collected or maintained for this 
clinical investigation .  
 
The Sponsor implements technical and physical access controls to ensure that Personal Information is 
accessible only to and proc essed only on a ‘need to know’ basis, including periodic review of access 
rights, and revocation of access when an individual’s employment is terminated or the individual 
transitions to a role that does not require access to Personal Information, and appro priate restrictions on 
physical access to premises, facilities, equipment, and records containing Personal Information.  
 
The Sponsor requires the investigational sites to transfer into Sponsor’s data management systems only 
pseudonymous Personal Informatio n (key -coded) necessary to conduct the Clinical Investigation, such 
as the patient’s medical condition, treatment, dates of treatment, etc. The Sponsor discloses as part of 
the clinical investigation informed consent process that some Sponsor representativ es still may see 
Personal Information at the participating sites for technical support of the participating physicians on the 
device implant or procedures, monitoring and quality control purposes. Confidentiality of Personal 
Information will be observed by  [CONTACT_404061]. The 
privacy of each subject and confidentiality of his/her information will be preserved in reports and when 
publishing any data.  
 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ADDRESS_509375] Confidential Information (including any 
Personal Information) against unauthorized access and/or interference by [CONTACT_26404], intrusion, theft, 
destruction, lo ss or alteration. Clinical Investigation data are encrypted in transit and at rest.  
 
The Sponsor maintains a Privacy Incident  procedure that complies in all respects with Applicable  Law 
and industry best practices.  
11.2 Data Management  Plan  
A Data Management Plan (DMP) will describe procedure s used for data review, data  cleaning, and 
issuing and resolving data discrepancies . If appropriate, the DMP may be updated throughout the 
duration of the clinical investigation . All revisions will be tracked an d document -controlled.  
11.[ADDRESS_509376]’s original medical 
records that corroborates data collected on the CRFs . In order to comply with these regulatory 
requirements/ GCP, the following information should be included in the subject record at a minimum and 
if applicable to the clinical investigation : 
• Medical history/physical condition of the subject before involvement in the clinical investigation  
sufficient to verify CIP entry criteria  
• Dated and signed notes on the day of entry into the clinical investigation  referencing the Sponsor, 
CIP number, subje ct ID number and a statement that informed consent was obtained  
• Dated and signed notes from each subject visit (for specific results of procedures and exams)  
• Adverse events reported and their resolution , including supporting documents , such as discharge 
summaries, catheterization laboratory reports, ECGs, and lab results including documentation of 
site awareness of SAEs and of investigator assessment of device relationship for  SAEs.  
• CIP-required laboratory reports and other tests , reviewed and annotated for  clinical significance 
of out of range results  (if applicable) .  
• Notes regarding  CIP-required and prescription medications taken during the clinical investigation  
(including start and stop dates)  
• Subject’s condition upon completion of or withdrawal from th e clinical investigation  
• Any other data required to substantiate data entered into the CRF  
• Patient reported outcome measures may be completed using CRF worksheets. These serve as 
the source documentation.  
11.4 Case Report Form Completion   
Primary data collectio n based on source -documented hospi[INVESTIGATOR_3491]/or clinic chart reviews will be 
performed clearly and accurately by [CONTACT_398801]. The 
investigator will ensure accuracy, completeness, legibility and timeliness of the data r eported to the 
Sponsor on the CRFs and in all required reports.  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ADDRESS_509377] Retention  
The Sponsor and Investigator/Site will archive and retain all documents pertaining to the clinical 
investigation  as per the applicable regulatory record retention requirements. The Investigator must obtain 
permission from Sponsor in writing before destroying or transferring control of any clinical investigation  
records.  
12.[ADDRESS_509378] /Medical Ethics Committee Review and Approval  
Institutional Review Board (IRB)/ Ethics Committee (EC) approval for the CIP and ICF/other written 
information provided to the patient will be obtained by [CONTACT_079] [INVESTIGATOR_403999] . The approval letter must be 
received prior to the start of t his clinical investigation  and a copy must be provided to the Sponsor.  
 
Any amendments to the CIP as well as associated ICF changes will be submitted to the IRB/EC and 
written approval obtained prior to implementation, according to each inst itution’s IRB/EC requirements.  
 
No changes will be made to the  CIP or ICF or other written information provided to the patient without 
appropriate approvals, including IRB/EC, the Sponsor, and the regulatory agencies (if applicable).  
 
Until the clinical investigation  is completed, the Investigator will advise his/her IRB/EC of the progress of 
this clinical investigation , per IRB/EC requirements. Written approval must be obtained from the IRB/EC 
yearly to continue the clinical investigation , or according t o each institution’s IRB/EC requirements.  
 
No investigative procedures other than those defined in this  CIP will be undertaken on the enrolled 
subjects without the written agreement of the IRB/EC and the Sponsor.  
13.0 CLINICAL INVESTIGATION  CONCLUSION  
The cl inical investigation  will be concluded when:  
• All sites are closed AND  
• The final report has been provided to investigators (within one year of the end of the 
investigation) or the Sponsor has provided formal documentation of clinical inves tigation closure . 
Upon conclusion of the study  (when the last subject completes their 12 month follow up) , investigators 
will return patients to their standard of care aspi[INVESTIGATOR_34308]. Study blinding will be maintained, even after 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ADDRESS_509379] of care aspi[INVESTIGATOR_34308], at the conclusion of the investigation. Refer to 
section 6.10 for additional details on study blinding.  
14.0 REPORTS AND PUBLICATIONS  
14.1 Sponsor Reports  
The Sponsor will submit study progress reports to all principle investigators fo r submission to reviewing 
IRBs/ECs at least yearly. The sponsor will submit a final report to appropriate regulatory bodies and to all 
principle investigators for submission to all reviewing IRBs/ECs and participating investigators within one 
year after co mpletion or termination.  The Sponsor will comply with all other reporting requirements.  
14.[ADDRESS_509380] be reviewed and approved by [CONTACT_21411] a timely manner to enable Sponsor 
review in compliance with the Sponsor’s publicat ion policy set forth in the Clinical Trial  Agreement.  
14.[ADDRESS_509381] 
safety and efficacy and may re duce non -surgical bleeding . 
15.2 Foreseeable Adverse Events and Anticipated Adverse Device Effects  
Risks associated with the specified device and aspi[INVESTIGATOR_404000] -Term  ([ADDRESS_509382] -implant)6 and Full Cohort (24 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ADDRESS_509383] -implant)[ADDRESS_509384] frequency of the risk 
associated with the placebo treatment arm are not known , but are hypothesized to be similar to the 
aspi[INVESTIGATOR_404001]. 
 
Table 7 – Expected Incidence Rate of Adverse Events  
Adverse Event  Short -Term (6 -month) 
MOMENTUM 3 
Results6 n=151 :  Full Cohort  (24-month) 
MOMENTUM 3 Results9 
n=515  
Death  11% 19% 
Bleeding  33% 44% 
Cardiac Arrhythmia  31% 36% 
Hepatic Dysfunction  5% 5% 
Driveline Infection  12% 23% 
Blood Infection  9% 15% 
Localized Infection (not 
associated with LVAS)  31% 41% 
Stroke  8% 10% 
Other Neurological Dysfunction  6% 12% 
Renal Dysfunction  11% 14% 
Respi[INVESTIGATOR_60064]  22% 22% 
Moderate or Severe Right Heart 
Failure  30% 34% 
Suspected Device Thrombosis  0% 1.4%  
 
15.[ADDRESS_509385] of care for LVAD pat ients along with 
vitamin K antagonists  and as such no new possible interactions are expected . No new medications are 
introduced in this study. For further detail, refer to the prescribing information for the anticoagulants in 
use – specifically vitamin K a ntagonist s (e.g. warfarin, fluindione, phenprocoumon , etc.) or aspi[INVESTIGATOR_248] . 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 49 of 81  
 
15.6 Steps  Taken to Control or Mitigate Risks  
Mitigations and treatment for all adverse events should be per the current practice standards/standards 
of care as  determined by [CONTACT_1188], except for the antithrombotic therapy for mitigation of 
thrombotic risk in enrolled patients, which is the subject of this study.  
Subject risk from study participation will be mitigated by [CONTACT_404062]. In addition to providing local product specific IFU, study 
staff will have undergo ne product, implant and study training prior to initia ting study activities, and all 
subjects will be closely monitored throughout the study duration at pre -specified time points to assess 
their clinical status.  
Specific information applicable to this study are listed below.  
• Inclusion/Exclusion criteria avoid patients who are at an inordinately elevated risk for 
complications including, but not limited to, women who are or may become pregnant , patients 
with a known allergy to aspi[INVESTIGATOR_248],  and patients who require  aspi[INVESTIGATOR_404002]-implant in the opi[INVESTIGATOR_871] .  
• It is suggested that patien ts possess a minimum 5th grade educational level and shall be  versed 
in basic computer literacy (i.e., Microsoft Windows® and Office software).  
• All users, including clinicians, patients, and caregivers, must be trained on system  operation and 
safety before  use. 
• All implanting surgeons  must be trained on HeartMate 3 surgical implant technique .  
• Clinical procedures (including LVAS settings) should be conducted under the  direction of the 
prescribing physician (Authorized Personnel) only.  
• A data safety monitori ng board  (DSMB ) will be monitoring adverse event data at regular intervals 
independently specified to assure safety is maintained throug hout the study. In the event of an 
unacceptable safety profile, the DSMB  will make a recommendation to pause or stop study 
enrollment while the  DSMB , Sponsor,  and steering committee determine if additional actions are 
necessary . Formal rules for making a recommendation to stop the study will be independently 
determined by [CONTACT_404063]. Rules will be contain ed within the DSMB Charter .  
15.[ADDRESS_509386] not been effectively mitig ated within this trial; the risks are 
comparable or superior to the HMII.  
All identified risks were managed through the risk management process and reduced as much as 
possible. The overall residual risks have been  deemed acceptable, per the risk management  process, 
and in consideration of the benefits provided by [CONTACT_209615]. The risk benefit analysis “basis for 
acceptance” for each of the residual risks are documented in the HeartMate 3 Risk Management Report.  
Removal of antiplatelet agents from the antith rombotic therapy of HM3 patients may reduce bleeding 
This study hypothesizes that there will be no additional thrombotic risk  based on the growing body of 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 50 of 81  
 
scientific evidence that shows the HM3 has a low thromboembolic profile5,9,11. However, bleeding eve nts, 
while decreased in comparison to a predicate device, remain burdensome9. All major prospective clinical 
trials conducted with the HM3 (MOMENTUM 3, CE Mark) have been in the context of a pr escribed 
antithrombotic regimen of aspi[INVESTIGATOR_403974] K antagonist. Within clinical studies9,10,16, as 
institutional changes to their standard of care18, or in response to increased bleeding risk17, modifications 
to the HM3 anticoagulation regimen have been explored. Prior to the introduction of the HM3, which has 
a decreased thrombotic profile relative to the HMII, studies investigating the need for aspi[INVESTIGATOR_404003]20-23.  
In conclusion, for the intended patient population, the probab le medical benefits of the HM3 outweigh the 
overall residual risk  and may be improved in the absence of antiplatelet agents as part of the 
antithrombotic regimen . This study aims to conclusively determine if antiplatelet agents are required as 
part of the HM3 antithrombotic regimen.  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 51 of 81  
 
APPENDIX I: ABBREVIATIONS AND ACRONYMS  
Abbreviation  Term  
ACE Angiotensin Converting Enzyme  
AE Adverse Event  
AI Aortic Insufficiency  
ALT Alanine Aminotransferase  
aPTT  Activated Partial Thromboplastin Time  
ARB Angiotensin II Receptor Blockers  
AST Aspartate Aminotransferase  
AVM  Arterio -venous malformation  
BTC Bridge -to-Candidacy  
BTT Bridge -to-Transplant  
BUN  Blood Urea Nitrogen  
CABG  Coronary Artery By[CONTACT_404064]-MB Creatinine Kinase Muscle/Brain  
CMS  Centers for Medicare and Medicaid SERVICES  
CNS  Central Nervous System  
CO Cardiac Output  
CPB Cardiopulmonary By[CONTACT_404065] [ADDRESS_509387] -
Market Approval Setting  
EQ-5D-5L EuroQ OL 5 Dimension 5 Level questionnaire  
FDA Food and Drug Administration  
GCP  Good Clinical Practices  
GI Gastrointestinal  
HAS-BLED  Hypertension, Abnormal renal and liver function, Stroke, Bleeding, 
Labile INR, Elderly, Drugs or Alcohol  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ADDRESS_509388] System  
LVEDD  Left Ventricular End Diastolic Diameter  
LVEF  Left Ventricular Ejection Fraction  
LVESD  Left Ventricular End Systolic Diameter  
MCS  Mechanical Circulatory Support  
MedDEV  Medical Device Directives  
MI Myocardial Infarction  
mITT  Modified Intention to Treat  
MOMENTUM3  Multi -center Study of MagLev Technology in Patients Undergoing 
MCS Therapy With HeartMate 3 ™ IDE Study  
MR Mitral Regurgitation  
MRI Magnetic Resonance Imaging  
MRS  Modified Rankin Score  
NPO  Nil per os. Latin for “Nothing through the Mouth”.  
NYHA  [LOCATION_001] Heart Association  
OUS  Outside the [LOCATION_002]  
PAD Diastolic Pulmonary Artery Pressure  
PAM  Mean Pulmonary Artery Pressure  
PAS Systolic Pulmonary Artery Pressure  
PCWP  Pulmonary Capi[INVESTIGATOR_404004] - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ADDRESS_509389]  
VAS Visual Analogue Scale  
VT Ventricular Tachycardia  
WBC  White Blood Cells  
 
  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 54 of 81  
 
APPEN DIX II: DEFINITIONS  
ADVERSE EVENT DEFINITIONS:  
 
1. Bleeding  
 
VAD-IMPLANT -RELATED BLEEDING:  
VAD-implantation -related bleeding (includes concomitant cardiac or non -cardiac surgical 
procedures) that requires:  
• Reoperation after closure of incision or incisions used to implant the VAD for the 
purpose of controlling bleeding  
• If ≥ 50 kg, ≥ 4U packed red blood cells (PRBC) within any [ADDRESS_509390] implant.  
• If < 50 kg, ≥ 20 cc/kg packed red blood cells (PRBC)  within any [ADDRESS_509391] implant.  
• Or any transfusion from 8 -14 days  
or exhibits:  
• Chest tube output > 2L within a 24 -h period  
 
MODERATE:  
Any overt, actionable sign of hemorrhage (e.g., more bleeding than would be expected 
for a clinical circumstance, including bleeding found by [CONTACT_3868]) that does not fit 
the criteria for a Severe  or Surgical  Bleeding Definitions  but meet s the following criteria:  
• requiring nonsurgical, medical intervention by a healthcare professional;   
and 
• leading to hospi[INVESTIGATOR_3820]  (unscheduled clinical visit or 
use of emergency services ). 
 
SEVERE:  
o Type A : (Meets  any of the below)  
• Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL (provided hemoglobin drop is 
related to bleed)  
• Any transfusion with overt bleeding  
o Type B : (Meets any of the below)  
• Overt bleeding plus hemoglobin drop 5 g/dL or greater (provided hemoglobin drop 
is related to bleed)  
• Cardiac tamponade  
• Bleeding requiring surgical intervention for control (excluding dental , nasal , skin, or 
hemorrhoid)  
• Hypotension attributable to bleeding and requiring intravenous vasoactive agents 
for hemodynamic support  
• Intracranial Hemorrhage that does not meet the definition of hemorrhagic stroke  
o Type C1: Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspi[INVESTIGATOR_404005] - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 55 of 81  
 
o Type C2:  Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation  
 
2. Cardiac Arrhythmias  
Any documented arrhythmia that results in clinical compromise (e.g., diminished VAD 
flow, oliguria, pre -syncope or syncope) that requires hospi[INVESTIGATOR_404006] a 
hospi[INVESTIGATOR_4408].  Cardiac arrhythmias are classified as 1 of 2 types:  
• Sustained ventricular arrhythmia requiring defibrillation or cardioversion.  
• Sustained supravent ricular arrhythmia requiring drug treatment or cardioversion.  
 
3. Device Thrombosis  
Device thrombosis is an event in which the pump or its conduits contain a thrombus that 
results in or could potentially induce circulatory failure. Suspected device thrombus is an 
event in which clinical or pump  parameters suggest thrombus on the blood con tacting 
components of the pump, cannula, or grafts. Signs and symptoms should include at least 
2 of the 3 following criteria:  
• Presence of hemolysis  
• Worsening heart failure or inability to decompress the left ventricle  
• Abnormal pump parameters  
 
Suspected pu mp thrombus should be accompanied by 1 or more of the following events 
or interventions:  
• Treatment with intravenous anticoagulation (e.g., heparin), intravenous 
thrombolytics (e.g., tPA), or intravenous antiplatelet therapy (e.g., eptifibatide, 
tirofiban)  
• Pump replacement  
• Pump explantation  
• Urgent transplantation (UNOS status 1A)  
• Stroke  
• Arterial non -CNS thromboembolism  
• Death  
 
Confirmed device thrombus is an event in which thrombus is confirmed by [CONTACT_1034]’s  
returned product analysis to be found within the blood contact[CONTACT_404066]. This can also be reported via direct vis ual 
inspection or by [CONTACT_404067].  
 
4. Hemolysis*  
A plasma -free hemoglobin value that is greater than 40 mg/dl, concomitant with a rise in 
serum LDH above three times the upper limit of normal, in association with clinical signs 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 56 of 81  
 
associated with hemolysis (e.g.,  anemia, low hematocrit, hyperbilirubinemia) occurring 
after the first  [ADDRESS_509392] -implant.  
*Hemolysis in the presence of worsening heart failure or inability to decompress the left 
ventricle or abnormal pump parameters should be reported as suspected device 
thrombosis, not as hemolysis   
 
5. Hepatic Dysfunction  
An increase i n any two of the following hepatic laboratory values (total bilirubin, aspartate 
aminotransferase/AST and alanine aminotransferase /ALT) to a level greater than three 
times the upper limit of normal for the hospi[INVESTIGATOR_307], beyond [ADDRESS_509393] -implant (or if hepat ic 
dysfunction is the primary cause of death).   
 
6. Hypertension  
Blood pressure elevation of a mean arterial pressure greater than 110 mm Hg, despi[INVESTIGATOR_325479]-hypertensive therapy.    
 
7. Major Infection  
A clinical infection accompanied by [CONTACT_77368], fever, drainage and/or leukocytosis that is 
treated by [CONTACT_14181] -microbial agents (non -prophylactic).  A positive culture from the infected 
site or organ should be present unless strong clinical evidence indicates the need for 
treatment despi[INVESTIGATOR_66533].  The  general categories of infection are listed below:  
Localized Non -Device Infection  
Infection localized to any organ system or region (e.g. mediastinitis) without evidence of 
systemic involvement (see sepsis definition), ascertained by [CONTACT_404068], viral, fungal or protozoal infection, 
and/or requiring empi[INVESTIGATOR_179774].  
Percutaneous Site and/or P ump Infection  
A positive culture from the skin and/or tissue surrounding the drive line or from the  tissue 
surrounding the external housing of a pump implanted within the body, coupled with the 
need to treat with antimicrobial therapy, when there is clinical evidence of infection such 
as pain, fever, drainage, or leukocytosis.  
Internal Pump Component, I nflow or Outflow Tract Infection  
Infection of blood -contact[CONTACT_404069].  
Sepsis  
Evidence of systemic involvement by [CONTACT_80601], manifested by [CONTACT_404070]/or hypotension.  
 
8. Myocardial Infarction  
Two categories of myocardial infarction will be identified:  
 
Peri-Operative Myocardial Infarction  
The clinical suspi[INVESTIGATOR_404007] -MB or Troponin > 10 
times the local hospi[INVESTIGATOR_404008], found within 7 days following VAD implant 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 57 of 81  
 
together with ECG findings consistent with acute myocardial infarction.  (This definition 
uses the higher suggested limit for serum markers due to api[INVESTIGATOR_404009].)  
 
Non-Perioperative Myocardial Infarction  
The presence at > [ADDRESS_509394] -implant of two of the following three criteria:   
 
• Chest pain which is characteristic of myocardial is chemia,  
• ECG with a pattern or changes consistent with a myocardial infarction, and  
• Troponin or CK (measured by [CONTACT_404071]/laboratory medicine 
methods) greater than the normal range for the local hospi[INVESTIGATOR_404010] (≥ 3% t otal CK).  This should be accompanied by a new regional LV or RV 
wall motion abnormality on a myocardial imaging study.  
 
9. Neurologic Dysfunction  
Any new, temporary or permanent, focal or global neurological deficit, ascertained by a 
standard neurological hi story and examination administered by a neurologist or other 
qualified physician and documented with appropriate diagnostic tests and consultation 
note; or an abnormality identified by [CONTACT_404072]. The examining physician 
will classify the ev ent as defined below:  
 
• Transient ischemic attack*, defined as an acute transient neurological deficit 
conforming anatomically to arterial distribution cerebral ischemia, which resolves 
in < 24 hours and is associated with no infarction on brain imaging (h ead CT 
performed >24 hours after symptom onset; or MRI)  
• Ischemic Stroke*: a new acute neurologic deficit of any duration associated with 
acute infarction on imaging corresponding anatomically to the clinical deficit, or a 
clinically covert ischemic stroke seen by [CONTACT_404073], without clinical 
findings of stroke or at the time of event recognition.  
• Hemorrhagic Stroke*: a new acute neurologic deficit attributable to intracranial 
hemorrhage (ICH), or a clinically covert ICH seen by [CONTACT_404074] g, without 
clinical findings of ICH at the time of event recognition.  
• Encephalopathy: Acute new encephalopathy** due to hypoxic -ischemic injury 
(HIE), or other causes, manifest as clinically evident signs or symptoms, or 
subclinical electrographic seizures  found by [CONTACT_404075], or ischemic brain 
injury not meeting one of ischemic stroke or ICH events as defined above.  
• Seizure of any kind  
•  Other neurological event (non -CNS event): examples include neuro muscular 
dysfunction or critical care neuropathy  
 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 58 of 81  
 
*Modified Rankin Score (MRS) will be used to classify the severity of all strokes . MRS will 
be captured at baseline, the time of stroke, and at [ADDRESS_509395] -stroke. MRS will be 
determined by [CONTACT_37702], defined as an independent, trained, and 
certified clinician. Severity will be defined as disabling (MRS  > 3) or nondisabl ing (MRS ≤ 
3). MRS is defined below.  
**Acute encephalopathy is a sign or symptom of some underlying cerebral disorder, and 
is manifest as depressed consciousness with or without any associated new global or 
multifocal neurologic deficits in cranial nerve,  motor, sensory, reflexes and cerebellar 
function.  
 
10. Renal Dysfunction  
Two categories of renal dysfunction will be identified:  
 
Acute Renal Dysfunction  
Abnormal kidney function requiring dialysis (including hemofiltration) in Subjects who did 
not require th is procedure prior to implant, or a rise in serum creatinine of greater than 3 
times baseline or greater than 5 mg/dL sustained for over 48 hours.  
 
Chronic Renal Dysfunction  
An increase in serum creatinine of 2 mg/dl or greater above baseline, or requireme nt for 
hemodialysis sustained for at least 90 days.  
 
11. Respi[INVESTIGATOR_404011], tracheostomy or the inability to 
discontinue ventilatory support within six days (144 hours) post -VAD implant.  This 
exclude s intubation for reoperation or temporary intubation for diagnostic or therapeutic 
procedures.  
 
12. Right Heart Failure  
Symptoms and signs of persistent right ventricular  dysfunction requiring RVAD 
implantation, or  requiring inhaled nitric oxide or inotropic t herapy  for a duration of more 
than 14 days at any time  after LVAD implantation.  To compare to prior studies, this study 
will begin collecting details of events involving nitric oxide or inotropic therapy for a 
duration of more than 7 days, whereas reportab le right heart failure will begin at 14 days 
of therapy.  
 
To further stratify right heart failure  (RHF) events, the following criteria will be used to  
identify a sub -category of persistent, clinically  significant RHF events:  
• Death due to right heart failure or  
• RVAD or  
• Hospi[INVESTIGATOR_404012]  
• Post-discharge inotropes or  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 59 of 81  
 
• > 30 consecutive days on inotropes . 
 
13. Arterial Peripheral  Thromboembolism   
An acute systemic arterial perfusion deficit in any non -cerebrovascular organ system due 
to thromboembolism confirmed by [CONTACT_10980]:  
 
1) Standard clinical and laboratory testing  
2) Operative findings  
3) Autopsy findings  
 
This definition excludes neurological events.  
 
14. Venous Thromboembolism Event  
Evidence of venous thromboembolic event (e.g. deep vein thrombosis, pulmonary 
embolism) by [CONTACT_404076].  
 
15. Other  
An event that causes clinically relevant adverse change s in the Subject’s health (e.g. 
cancer)  not otherwise categorized above . 
 
  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 60 of 81  
 
NEW YORK HEART ASSOCIATION (NYHA) CLASSIFICATION  
 
NYHA Classification  Definition  
I Cardiac disease without resulting limitations of physical activity. Ordinary 
physical activity does not cause undue fatigue, palpi[INVESTIGATOR_814], dyspnea or 
anginal pain.  
II Cardiac disease resulting in slight limitation of physical activity. Subjects are 
comfortable at rest. Ordinary physical activity results in fatigue, palpi[INVESTIGATOR_332], 
dyspnea or anginal pain.  
IIIA Cardiac disease resulting in marked limitations of physical activity. Subjects 
are comfortable at rest. Less than ordinary physical activity causes fatigue, 
palpi[INVESTIGATOR_332], dyspnea, or anginal pain.  
IIIB Cardiac disease resulti ng in marked limitations of physical activity. Subjects 
are comfortable at rest. Mild physical activity causes fatigue, palpi[INVESTIGATOR_332], 
dyspnea, or anginal pain.  
IV* Cardiac disease resulting in inability to carry on any physical activity without 
discomfort.  Symptoms of cardiac insufficiency or of the anginal syndrome 
may be present even at rest. If any physical activity is undertaken, discomfort 
is increased.  
 
  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 61 of 81  
 
INTERMACS PROFILE  
 
INTERMACS  
Profile*  Definition  
1 Critical cardiogenic shock describes a patient who is “crashing and burning”, in which 
a patient has life -threatening hypotension and rapi[INVESTIGATOR_404013], with critical organ hypoperfusion often confirmed by [CONTACT_404077].  
2 Progressive decline describes a patient who has been demonstrated “dependent” on 
inotropic support but nonetheless shows signs of continuing deterioration in nutrition, 
renal function, fluid retention, or other major status indicator. Patient profile 2 can  also 
describe a patient with refractory volume overload, perhaps with evidence of impaired 
perfusion, in whom inotropic infusions cannot be maintained due to tachyarrhythmias, 
clinical ischemia, or other intolerance.  
3 Stable but inotrope dependent desc ribes a patient who is clinically stable on mild -
moderate doses of intravenous inotropes (or has a temporary circulatory support 
device) after repeated documentation of failure to wean without symptomatic 
hypotension, worsening symptoms, or progressive org an dysfunction (usually renal). 
It is critical to monitor nutrition, renal function, fluid balance, and overall status 
carefully in order to distinguish between a patient who is truly stable at Patient Profile 
[ADDRESS_509396] orth opnea, 
shortness of breath during ADL such as dressing or bathing, gastrointestinal 
symptoms (abdominal discomfort, nausea, poor appetite), disabling ascites or severe 
lower extremity edema. This patient should be carefully considered for more intensive 
management and surveillance programs, by [CONTACT_404078].  
[ADDRESS_509397] 
year.  
7 Advanced NYHA Class 3 describes a patient who is clinically stable with a reasonable 
level of comfortable activity, despi[INVESTIGATOR_404014]. This patient is usually able to walk more than a block. Any decompensation 
requiring intravenous diuretics or hospi[INVESTIGATOR_404015] a Patient Profile 6 or lower.   
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 62 of 81  
 
MODIFIED RANKIN SCORE (MRS)  
 
MRS  Definition1  
0 No observed neurological symptoms  
1 No significant neurological disability despi[INVESTIGATOR_5119]; able to 
carry out all usual duties and activities  
2 Slight neurological disability; unable to carry out all previous 
activities, but able to look after own affairs without assistance  
3 Moderate neurological disab ility; requiring some help, but able to 
walk without assistance  
4 Moderate severe neurological disability; unable to walk without 
assistance and unable to attend to own bodily needs without 
assistance  
5 Severe neurological disability; bedridden, incontinent and 
requiring constant nursing care and attention as a result of a 
neurological deficit  
[ADDRESS_509398] implant.   
 
  
 
1 van Swieten J, Koudstaal P, Visser M, Schouten H, et al (1988). “Interobserver agreement for the assessment of 
handicap in stroke Subjects ”. Stroke  19 (5): 604 -607 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 63 of 81  
 
APPENDIX III: STUDY CONTACT [CONTACT_404079] a vailable under separate cover by 
[CONTACT_404080].  
 
Project Management Contact  
 
[CONTACT_404081]  
[ADDRESS_509399]  
Santa Clara , CA, [ZIP_CODE]  
[LOCATION_003] 
Phone:  +[PHONE_8350]  
E-mail: nina.sinanovic @abbott.com  
 
 
Clinical Safety Contact  
 
[CONTACT_404082]  
168 Middlesex Turnpi[INVESTIGATOR_403964], MA, [ZIP_CODE]  
[LOCATION_003] 
E-mail: AdverseEvent @abbott.com  
 
Requests for further clarifications on submitted reports can be sent to 
[EMAIL_7720] . 
  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 64 of 81  
 
APPENDIX IV: INFORMED CONSENT FORM  
The study  template informed consent form is available  under a separate cover . 
 
 
  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 65 of 81  
 
APPENDIX V: MONITORING PLAN  
A copy of the Monitoring Plan can be obtained upon request from the  Sponsor  Clinic al Project Manager.  
  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 66 of 81  
 
APPENDIX VI: DEVICE POSITION SUBSTUDY PROTOCOL  
Study Title  Assessment of HeartMate [ADDRESS_509400] device (LVAD) is now the most 
frequently utilized surgical therapy for treatment of patients with advanced heart 
failure (HF) refractory to medical management.  Previous studies have 
demonstrated that inflow cannula malposition, which occurs 1) due to incorrect 
surgical placement, or 2) as a consequence of device migration, is associated with 
significant adverse events including pump thrombosis, stroke and persistent heart 
failure due to the inability t o provide adequate left ventricular unloading and device 
flow.( 1) 
    Specific surgical configurations have not been studied in depth, and its influence 
on hemocompatatibility -related events associated with LVAD therapy remains 
poorly understood.( 2) Thrombogenesis in patients with an LVAD is at least, in part, 
attributable to nonphysiological blood flow characteristics: shear environments, as 
well as high spatial gradients and high -frequency temporal fluctuations, which lead 
to platelet activation. This adverse hemodynamic environment may be 
exacerbated by [CONTACT_404083]. Anecdotal evidence 
suggests that surgical implantation of the inflow cannula at different angles with 
respect to the api[INVESTIGATOR_404016].( 3-5) 
     Prior studies investigating inflow cannula malposition have utilized various 
reference  lines to determine optimal inflow cannula position.  Typi[INVESTIGATOR_897], these 
reference lines utilize the spi[INVESTIGATOR_53530] a vertical reference line and a horizont al line 
drawn perpendicular to the vertical line usually positioned at the apex of the right 
diaphragm serves as a horizontal reference point.( 3-5)  However, this approach 
does not take into consideration differences in anatomy of the heart in relation to 
the spi[INVESTIGATOR_404017].  Optimal inflow position in oriented to the orifice of the 
mitral valve.  Thus, the utility of these reference lines to identify the orifice of the 
mitral valve is brought into question.  
     This substudy utilizes a simple techn ique to identify a more anatomical 
reference point to assess HeartMate 3 inflow cannula position.  A radiopaque 
surgical marker (i.e., surgical clip) will be placed on the anterior surface of the 
aortic root below the sino -tubular ridge of the aorta just a bove the ostia of the right 
coronary artery.   
     The surgical clips used in this study are generally standard to use in cardiac 
surgery for both hemostasis and as radiopaque markers. They have been used for 
the development of this substudy in [ADDRESS_509401] -implant at a single center without safety concerns (data not 
published). The location of the clip reduces the likelihood of interference with the 
coronary artery. Placement of the clips will be under direc t visualization and will 
not prolong the implant procedure. Participation in this substudy is not expected 
to present appreciable additional risk. This substudy will not affect the main 
objectives of the ARIES HM3 clinical trial.  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ADDRESS_509402] 
above the ostia of the right coronary artery to be used as a surrogate anatomical 
reference or landmark to more optimally assess HeartMate 3 inflow cannula 
position.  Validation will be performed by [CONTACT_58833]:  
1. The safety and feasibility of placing and visualizing the radiopaque 
marker;  
2. The variation in cannula angulation relative to the radiopaque marker and 
cannula positional changes over time;  
3. The relationship betwee n the initial cannula angulation or its change over 
time with adverse clinical outcomes and functional capacity, as an 
exploratory analysis.  
 
Study Populations  Subjects enrolled in the ARIES HM3 study who also meet eligibility requirements 
for this substudy at participating centers.  
Study Design  Multi -center, prospective, non -controlled, non -randomized, observational sub -
study within ARIES  
 
Number of 
Subjects  Per ARIES HM3 study  
Number of Centers  
 Up to [ADDRESS_509403] unacceptable risk based upon technical reasons 
or patient anatomy.  
2. Subjects undergoing placement of the HeartMate 3 device through a  
minimally -invasive approach where sternotomy or upper sternotomy will not be 
performed and access to the anterior surface of the aorta below the sino -
tubular ridge is not feasible.  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 68 of 81  
 
Intervention  A radiopaque surgical marker (i.e., surgical clip) will be placed on the anterior 
surface of the aortic root midway between the sino -tubular ridge of the aorta and 
the ostia of the right coronary artery.  The radiopaque marker will include 
placement of [ADDRESS_509404] surgical clips (manufacturer, size, pi[INVESTIGATOR_1103] ; see Figures 1, 
2A and B, 3 and 4 ) attached to the advent itia of the aorta and positioned as 
described above.  
 
Assessments  Anteroposterior (AP) and lateral radiographs  will be captured prior to discharge  
(but within 30 days of implant) and at the 3 -month follow up visit.  Radiographs 
will be obtained by a fixed radiography (fixed x -ray) and sent to the study 
sponsor in DICOM format. If standard of care (SOC), chest x -ray computed 
tomography (CT) scans will be obtained in addition to the radiographs.  
References  
1. Chivukula VK, Beckman JA, Prisco AR, et al.  Left v entricular assist device 
inflow cannular angle and thrombosis risk.  Circulation: Heart Failure.  
2018;11:e004325.  
2. Mancini D, Colombo PC. Left ventricular assist devices: a rapi[INVESTIGATOR_404018]. J Am Coll Cardiol. 2015;65:2542 –2555.  
3. Taghavi S, Ward C, Jayarajan SN, Gaughan J, Wilson LM, Mangi 
AA. Surgical technique influences HeartMate II left ventricular assist device 
thrombosis. Ann Thorac Surg . 2013 ; 96:1259 –1265.   
4. Atkins BZ, Hashmi ZA, Ganapathi AM, Harrison JK, Hughes GC, Rogers 
JG, Milano CA.  Surgical correction of aortic valve insufficiency after left 
ventricular assist device implantation. J Thorac Cardiovasc 
Surg . 2013 ; 146:1247 –1252.   
5. Bhama J, Eckert C, Lockard K, Shiose A, Bermudez C, Teuteberg J, 
Ramani R, Simon M, Ba dhwar V, Kormos R.  Does LVAD inflow cannula 
position contribute to the development of pump thrombosis requiring 
device exchange? J Am Coll Cardiol . 2013 ; 61:E719.  
 
 
  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 69 of 81  
 
Figure 1:  Acceptable Anteroposterior   and Lateral Chest Radiograph Demonstrating Placement of a 
Radiopaque marker (two standard surgical clips). Clips are placed on the anterior surface of the aorta 
positioned halfway between the sino -tubular ridge of the aorta and the right coronary artery. Note: the full 
body of the HM3 is visible within the radiograph.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  

 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 70 of 81  
 
Figure 2 A:  Measurement Method on Anteroposterior  and Lateral Chest Radiograph. Radiopaque 
marker (two standard surgical clips) on the anterior surface of the aorta is positioned halfway between 
the sino -tubular ridge of the aorta and the right coronary artery (Red Arrow).  Black line indicates center 
line of the HeartMate 3 inflow canula.  The dotted red line indicates the degree of deviation from the 
reference point (s urgical radiopaque marker).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  

 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 71 of 81  
 
Figure 2 B:  Measurement Method on Anteroposterior  and Lateral Chest Radiograph. Radiopaque 
marker (two standard surgical clips) on the anterior surface of the aorta is positioned halfway between 
the sino -tubular ridge of the aorta and the right coronary artery (Red Circle).  Black line indicates center 
line of the HeartMate 3 inflow canula.  The dotted red line indicates the degree of deviation from the 
reference point (surgical radiopaque  marker).  
  

 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 72 of 81  
 
Figure 3:  Radiopaque Surgical Marker  
 
 
 
 
  

 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 73 of 81  
 
Figure 4:  Radiopaque Surgical Marker  
 
  

 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 74 of 81  
 
APPENDIX VII: REVISION HISTORY  
This CIP may be amended as appropriate by [CONTACT_1034]. Rationale will be included with each amended 
version in the revision history table below. The version number and date of amendments will be 
documented.  
 
IRB/EC and relevant Regulatory Authorities, if a pplicable, will be notified of amendments to the CIP.  
 
Amendment 
Number  Version  Date  Details  Rationale  
Not 
Applicable  A 22AUG [ADDRESS_509405] release of CIP  NA 
1 B 15JAN2020  DSMB  is unblinded ; 
Sponsor is fully blinded.  
 
 
Update Statistics Section to 
reflect updated analysis 
plan including removal of 
superiority analysis, 
combining secondary and 
safety endpoints, adding 
secondary endpoints .  
 
Add Device  Position 
Substudy  
 
 
 
Clarify transition to open 
label  and add 72 -hour 
cessation window  
 
 
Add “Other ” Adverse Event 
Definition and clarify 
Moderate Bleeding 
definition  
 
Remove [ADDRESS_509406] on 
outcomes  
 
Allow 72 -hour cessation of 
treatment arm medication prior 
to transition to open label f or 
treatment of adverse events.  
 
All adverse events will be 
collected.  
 
 
 
Regulation not applicable to 
this study  
 
 
n/a 
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 75 of 81  
 
2 C 13MAR 2020  Relabeled Primary 
Endpoint analysis 
population as mITT 
population and defined ITT 
Population  
 
Corrected 97.5% 
confidence limit in primary 
endpoint analysis method  Using more unified definitions 
of populations as well as 
defining an ITT population for a 
sensitivity analysis  
 
 
Correction  
 
  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 76 of 81  
 
APPENDIX VIII: CIP SUMMARY  
Clinical 
Investigation 
Name [CONTACT_404088]3  
CRD_971  
Title Antiplatelet  Removal and Hemocompat Ibility EventS with the 
HeartMate 3 Pump  
Background  Heart failure (HF) is a growing epi[INVESTIGATOR_901], with 915,000 new cases diagnosed 
each year, resulting in over 1 million hospi[INVESTIGATOR_404019] (US) healthcare system over $[ADDRESS_509407] 
devices (LVAD) are increasingly being used for treating patients with advanced 
heart failure as they have demonstrated improved survival over optimal medical 
management2. Progressively improving outcomes with newer LVAD technology 
has led to LVAD therapy becoming a mainstay in the treatment of advanced 
heart failure3, however, LVAD therapy has bee n beleaguered by 
[CONTACT_404024] – namely thrombosis, stroke and 
bleeding4. Within the prospective randomized multicenter MOMENTUM 3 
clinical trial, the HeartMate 3 (HM3) Left Ventricular Assist System (LVAS; 
Abbott, Chicago, IL, Study Sponsor) showed a decrease in hemocompatibility 
related adverse events relative to the HeartMate II (HM II) LVAS (Abbott, 
Chicago, IL)5. This included decreases in pump thrombosis6, stroke7-9, and 
bleeding9 event rates . Despi[INVESTIGATOR_403968] a high resid ual risk of 
bleeding persists in patients treated with the HM3 LVAD9. Patients implanted 
with the HM3 pump are treated with a combination of antiplatelet and 
anticoagulation therapy but the rol e and implications of this regimen in 
determining the burden of hemocompatibility related adverse events have not 
been adequately investigated9,10. Whether antiplate let therapy is essential in 
concert with anticoagulation in treating such patients remains unknown.  
 
Objective  To study the safety and efficacy of an anti -platelet -free antithrombotic regimen 
in patients with advanced heart failure treated with the HM [ADDRESS_509408] safety and efficacy and may reduce non -surgical 
bleeding  
Clinical 
Investigation 
Design  Prospective, randomized, double -blinded, placebo -controlled clinical 
investigation of advanced heart failure patients treated with the HM3 with two 
different antithrombotic regimens: vitamin K antagonist with aspi[INVESTIGATOR_248] v ersus 
vitamin K antagonist with placebo  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ADDRESS_509409] System (LVAS)  
 
In the US, the HM3 LVAS is indicated for providing mechanical circulatory 
support in patients with advanced refractory left ventricular heart failure (e.g. 
pending cardiac tr ansplantation or myocardial recovery, or for permanent 
support). In Europe, the HM3 LVAS is intended to provide long term 
hemodynamic support in patients with advanced, refractory left ventricular heart 
failure. It is intended either for temporary support,  such as a bridge to cardiac 
transplantation (BTT), or as permanent destination therapy (DT) and it is 
intended for use inside or outside the hospi[INVESTIGATOR_307]. In Canada, The HM3 LVAS is 
indicated for providing mechanical circulatory support in patients with advan ced 
refractory left ventricular heart failure (e.g., pending cardiac transplantation or 
myocardial recovery, or for permanent support).  
Treatment Arm 
Medication  Aspi[INVESTIGATOR_248] (100 mg – active ingredient: Acetylsalicylic acid)  
OR 
Placebo (ALMAC Group, Craigavon, [LOCATION_006])  
Study Sites  Up to 50 US and international sites  
Patient Protection 
Procedures  This study will employ an independent clinical events committee (CEC), which 
will remain blinded to subject randomization, to adjudicate primary endpoint 
related adverse events. Study monitoring will be performed by [CONTACT_404084] (DSMB), which will be unblinded to population 
randomization and determine independent rules for safety oversight.   
Primary Endpoint  Composite of Survival free of any non -surgical1 major hemocompatibility related 
adverse event2 at 1-year post implant.  
 
1Non-surgical – any event occurring > [ADDRESS_509410] implant  
 
2Major Hemocompatibility Related Adverse Event:  
• Stroke  
• Pump Thrombosis (suspected or confirmed)  
• Bleeding (including intracr anial bleeds that do not meet the stroke 
definition)  
• Arterial Peripheral Thromboembolism  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 78 of 81  
 
Primary Endpoint 
Evaluation   The primary endpoint composite success rate will be calculated for each 
treatment arm based on the number of subjects who survive to 12 months with 
no primary endpoint events divided by [CONTACT_404085] (mITT)  population. The placebo arm will 
be considered non -inferior to the aspi[INVESTIGATOR_404020]-
sided 9 7.5% confidence limit of the risk difference in the composite success 
between treatment arms (Placebo -arm minus Aspi[INVESTIGATOR_248] -arm) is greater than the 
non-inferiority margin (10%).   
Number of 
Subjects Required 
for Inclusion in 
Clinical 
Investigation  Results from the MOMENTUM 3 trial were used to derive a point estimate of 
71% survival to 1 year free of any major hemocompatibility related adverse 
events in the aspi[INVESTIGATOR_403993]. It is assumed that in the absence of aspi[INVESTIGATOR_248] a 
2% improvement in the composite endpoint will be noted, mainly due to the 
reduction of bleeding complications without a change in thromboemb olic 
complications. Based on these assumptions 220 patients will need to be 
enrolled in each arm (440 total) to achieve 80% power to prove that the placebo 
group is non -inferior to the aspi[INVESTIGATOR_403994] a non -inferiority margin of 10% 
with the Farrington -Manning risk difference approach to non -inferiority at a one -
sided alpha = 0.025. To account for an expected 30% dropout rate associated 
with events occurring [ADDRESS_509411] implant, up to 628 patients will be 
randomized in the trial. Sample size calculat ions were performed using PASS 
15 software.  
Secondary 
Endpoint  • Non-surgical Major Hemorrhagic Events  
• Non-surgical Major Thrombotic Events  
• Survival  
• Stroke Rates,  
• Pump Thrombosis Rates  
• Bleeding Rates, including:  
o Non-surgical Bleeding  
o Moderate Bleeding  
o Severe Bleeding  
o Fatal Bleeding  
o GI Bleeding  
 
Descriptive 
Endpoints  Hemocompatibility Score, Rehospi[INVESTIGATOR_602], Economic Cost Implications  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ADDRESS_509412] Follow -up − Baseline  
− Implant  
− Randomization  
− Discharge  
− Week 1 ± 3 days  
− Month 1 ± 7 days  
− Month 3 ± 30 days  − Month 6 ± 30 days  
− Month 9 ± 30 days  
− Month 12 ± 30 days  
− Every 6 month ± [ADDRESS_509413] has completed the 12 -
month follow -up. 
Inclusion Criteria  • Subject will receive the HeartMate [ADDRESS_509414] of care (SOC) in 
accordance with the approved indications for use in the country of implant.  
• Subject will receive the HeartMate [ADDRESS_509415] durable VAD.  
• Subject must provide written informed consent prior to any clinical 
investigation related procedure.  
• In patients of child bearing capability, not currently pregnant and on 
appropriate contraception.  
Exclusion Criteria  • Post-implant additional temporary or permanent mechanical circulatory 
support (MCS) post -implant (other than the HM3 LVAD).  
• Post-implant Investigator mandated antiplatelet therapy for other conditions 
(including mandated presence or absence of antiplatelet agent).  
• Patients who are nil per os (NPO) post -implant through day 7.  
• Subjects with a known allergy to acetylsalicylic acid.  
• Participati on in any other clinical investigation(s) involving an MCS device, 
or interventional investigation(s) likely to confound study results or affect 
study outcome.  
• Presence of other anatomic or comorbid conditions, or other medical, social, 
or psychological co nditions that, in the investigator’s opi[INVESTIGATOR_1649], could limit the 
subject’s ability to participate in the clinical investigation or to comply with 
follow -up requirements, or impact the scientific soundness of the clinical 
investigation results.  
 
  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 80 of 81  
 
APPENDIX IX: REFERENCES  
1 Mozaffarian, D.  et al.  Heart Disease and Stroke Statistics -2016 Update: A Report From the 
American Heart Association. Circulation  133, e38 -360, doi:10.1161/CIR.0000000000000350 
(2016).  
[ADDRESS_509416] device for end -stage heart failure. N 
Engl J Med  345, 1435 -1443, doi:10.1056/NEJMoa012175 (2001).  
3 Cook, J. L.  et al.  Recommendations for the Use of Mechanical Circulatory Support: Ambulatory 
and Community Patient Care : A Scientific Statement From the American Heart Association. 
Circulation  135, e1145 -e1158, doi:10.1161/CIR.0000000000000507 (2017).  
[ADDRESS_509417] systems: a complex 
weave. Eur Heart J  40, 673 -677, doi:10.1093/eurheartj/ehx036 (2019).  
5 Uriel, N.  et al.  Hemocompatibility -Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A 
Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure. 
Circulation  135, 2003 -2012,  doi:10.1161/CIRCULATIONAHA.117.028303 (2017).  
6 Mehra, M. R.  et al.  A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. N 
Engl J Med  376, 440 -450, doi:10.1056/NEJMoa1610426 (2017).  
7 Colombo Paolo, C.  et al.  Comprehensive Analysis of Stroke in the Long -Term Cohort of the 
MOMENTUM 3 Study. Circulation  139, 155 -168, doi:10.1161/CIRCULATIONAHA.118.037231 
(2019).  
8 Mehra, M. R.  et al.  Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart 
Failure. N Engl J Med  378, 1386 -1395, doi:10.1056/NEJMoa1800866 (2018).  
[ADDRESS_509418] Device - Final Report. N 
Engl J Med  0, null, doi:10.1056/NEJMoa1900486 (2019).  
10 Netuka, I.  et al.  Evaluation of low -intensity anti -coagulation with a fully magnetically levitated 
centrifugal -flow circulatory pump -the MAGENTUM 1 study. J Heart Lung Transplant  37, 579 -586, 
doi:10.1016/j.heal un.2018.03.002 (2018).  
11 Schmitto, J. D.  et al.  Long -term evaluation of a fully magnetically levitated circulatory support 
device for advanced heart failure —two-year results from the HeartMate 3 CE Mark Study. 
European journal of heart failure  21, 90-97, doi:10.1002/ejhf.1284 (2019).  
12 Saeed, D.  et al.  Two-Year Outcomes in Real World Patients Treated with Heartmate 
3<sup>TM</sup> Left Ventricular Assist Device for Advanced Heart Failure: Data from the 
ELEVATE Registry. The Journal of Heart and Lung Transp lantation  38, S67, 
doi:10.1016/j.healun.2019.01.153 (2019).  
13 Heatley, G.  et al.  Clinical trial design and rationale of the Multicenter Study of MagLev 
Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 
(MOMENTUM 3) investigational device exemption clinical study protocol. J Heart Lung 
Transplant  35, 528 -536, doi:10.1016/j.healun.2016.01.021 (2016).  
14 Mehra, M. R.  et al.  A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. N 
Engl J Med  376, 440 -450, doi:10.1056/NEJMoa1610426 (2016).  
15 Uriel, N. & Mehra, M. Long -Term Burden  of Hemocompatibility Related Adverse Events in the 
MOMENTUM 3 Trial: Final Analysis of the 1028 Patient Cohort. The Journal of Heart and Lung 
Transplantation  38, S67, doi:10.1016/j.healun.2019.01.152 (2019).  
[ADDRESS_509419] awal of Anticoagulation Therapy in the Heartmate 3 
Pump. The Journal of Heart and Lung Transplantation  38, S113, 
doi:10.1016/j.healun.2019.01.264 (2019).  
17 Consolo, F., Raimondi Lucchetti, M., Tramontin, C., Lapenna, E. & Pappalardo, F. Do we need 
aspi[INVESTIGATOR_404021] 3 patients? European journal of heart failure , doi:10.1002/ejhf.1468 (2019).  
 Redacted - ABT-CIP-[ZIP_CODE] Ver. C  
Study Name: [CONTACT_404087]3  
Clinical Investigation Plan  
 
 
This confidential document is the property of Abbott and shall not be reproduced, distributed, disclosed or used without the 
express written consent of Abbott  
Template: [ZIP_CODE] Rev. F   Page 81 of 81  
 
18 Lim, H. S., Ranasinghe, A., Mascaro, J. & Howell, N. Discontinuation of Aspi[INVESTIGATOR_404022] [ADDRESS_509420] Device. ASAIO Journal (American Society For  Artificial Internal Organs: 
1992) , doi:10.1097/MAT.0000000000000859 (2018).  
[ADDRESS_509421] of Aspi[INVESTIGATOR_404023]. 
New England Journal of Medicine  379, 1509 -1518, doi:10.1056/NEJMoa1805819 ( 2018).  
20 Katz, J. N.  et al.  Safety of reduced anti -thrombotic strategies in HeartMate II patients: A one -year 
analysis of the US -TRACE Study. Journal of Heart and Lung Transplantation  34, 1542 -1548, 
doi:10.1016/j.healun.2015.06.018 (2015).  
21 Netuka, I.  et al. Outcomes in HeartMate II Patients With No Antiplatelet Therapy: 2 -Year Results 
From the European TRACE Study. The Annals of thoracic surgery  103, 1262 -1268, 
doi:10.1016/j.athoracsur.2016.07.072 (2017).  
[ADDRESS_509422] Device. ASAIO journal  63, 731 -735, 
doi:10.1097/mat.0000000000000561 (2017).  
[ADDRESS_509423] device 
patients? A single -centre experience. European journal of cardio -thoracic surgery : official journal 
of the European Association for Cardio -thoracic Surgery  45, 55-59; discussion 59 -60, 
doi:10.1093/ejcts/ezt228 (2014).  
 